The University of Chicago Header Logo

George Bakris

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Endocrinology
AddressChicago IL 60637
Phone+1 (773) 702-7936
Email
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Director, ASH Comprehensive Hypertension Center

    Collapse Biography 
    Collapse awards and honors
    2014Astra Zeneca Award for Innovation in Therapeutics, International Society of Hypertension
    2009Honorary Doctorate Degree, University of Thessaloniki Greece
    2012 - 2015Top Doctors in USA, Castle Connelly
    2019 - 2019Irvine Page-Alva Bradley Lifetime Achievement Award-Am Heart Assoc. BP , Am Heart Assoc. BP Council
    2021 - 20212021 National Kidney Foundation of Illinois Lifetime Service-Achievement Award, National Kidney Foundation
    2023 - 2023Luminary in Cardiometabolic Medicine Award-, Heart in Diabetes Group
    2023 - 2023Honorary Doctorate Degree, University of Athens, GREECE
    2023 - 2023Hippokrates Lifetime Academic Contribution Award, University of Athens School of Medicine
    2015 - 2023Top Doctors in USA, Castle Connelly
    2015 - 2015Hypertension Lecturer of the Year- , Belgium Hypertension Society

    Collapse Research 
    Collapse research activities and funding
    U01DK048643     (BAKRIS, GEORGE LOUIS)Aug 15, 1994 - Jun 30, 2008
    NIH
    AASK Cohort Study
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Razaghizad A, Aziz H, Zhang GK, Ferreira JP, White WB, Mehta CR, Bakris GL, Zannad F, Sharma A. Pathophysiological Sex-Differences in Heart Failure Progression after Acute Coronary Syndrome: Insights from the EXAMINE Trial. J Card Fail. 2023 Nov 06. PMID: 37939897.
      Citations:    Fields:    
    2. Heerspink HL, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, Karpefors M, Wheeler DC, Bakris G, Perkovic V, Nkulikiyinka R, Rossert J, Gasparyan SB. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023 Oct 24. PMID: 37872654.
      Citations:    Fields:    
    3. Kalantar-Zadeh K, Forfang D, Bakris G, Martin KJ, Moe SM, Sprague SM. Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet. Kidney360. 2023 Oct 23. PMID: 37870525.
      Citations:    Fields:    
    4. Bakris GL, Yang YF, McCabe JM, Liu JR, Tan XJ, Benn VJ, Pitt B. Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. Am J Hypertens. 2023 Oct 13; 36(11):612-618. PMID: 37471468; PMCID: PMC10570658.
      Citations:    Fields:    
    5. Desai AS, Sweetser MT, Bakris GL. Zilebesiran for Hypertension. Reply. N Engl J Med. 2023 Oct 12; 389(15):1439-1440. PMID: 37819965.
      Citations:    Fields:    Translation:Humans
    6. Perakakis N, Bornstein SR, Birkenfeld AL, Linkermann A, Demir M, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Kolkhof P, Lawatscheck R, Scott C, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators. Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes Obes Metab. 2023 Oct 10. PMID: 37814928.
      Citations:    Fields:    
    7. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Kirkman MS. Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023 10 01; 46(10):1740-1746. PMID: 37471272; PMCID: PMC10516242.
      Citations:    Fields:    Translation:Humans
    8. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Kirkman MS. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023 10 01; 46(10):e151-e199. PMID: 37471273; PMCID: PMC10516260.
      Citations: 2     Fields:    Translation:Humans
    9. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, FIDELIO-DKD Investigators . Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897. Diabetes Care. 2023 Sep 01; 46(9):1721. PMID: 37310695; PMCID: PMC10465986.
      Citations:    Fields:    
    10. Naaman SC, Bakris GL. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 2023 09 01; 46(9):1574-1586. PMID: 37625003; PMCID: PMC10547606.
      Citations: 1     Fields:    Translation:Humans
    11. Baeres FMM, Bosch-Traberg H, Gislum M, Gough SCL, Idorn T, Lawson J, Mersebach H, Rossing P, Bakris G, Mahaffey KW, Mann JFE, Perkovic V, Tuttle K, Pratley R. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 08 31; 38(9):2041-2051. PMID: 36651820; PMCID: PMC10469096.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    12. Heerspink HJL, Vart P, Jongs N, Neuen BL, Bakris G, Claggett B, Vaduganathan M, McCausland F, Docherty KF, Jhund PS, Solomon SD, Perkovic V, McMurray JJV. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023 11; 25(11):3327-3336. PMID: 37580309.
      Citations:    Fields:    Translation:Humans
    13. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Sue Kirkman M. Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin Chem. 2023 08 02; 69(8):777-784. PMID: 37562009.
      Citations:    Fields:    Translation:Humans
    14. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Kirkman MS. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin Chem. 2023 08 02; 69(8):808-868. PMID: 37473453.
      Citations:    Fields:    Translation:Humans
    15. Agarwal R, Pitt B, Rossing P, Anker SD, Filippatos G, Ruilope LM, Kovesdy CP, Tuttle K, Vaduganathan M, Wanner C, Bansilal S, Gebel M, Joseph A, Lawatscheck R, Bakris GL. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. 2023 08 01; 8(8):732-741. PMID: 37314801; PMCID: PMC10267848.
      Citations:    Fields:    Translation:Humans
    16. Rosas SE, Ruilope LM, Anker SD, Pitt B, Rossing P, Bonfanti AAC, Correa-Rotter R, González F, Munoz CFJ, Pergola P, Umpierrez GE, Scalise A, Scott C, Lawatscheck R, Joseph A, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis. Kidney Med. 2023 Oct; 5(10):100704. PMID: 37745646; PMCID: PMC10514441.
      Citations:    
    17. Blazek O, Bakris GL. Slowing the Progression of Diabetic Kidney Disease. Cells. 2023 07 31; 12(15). PMID: 37566054; PMCID: PMC10417620.
      Citations:    Fields:    Translation:Humans
    18. Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee S, Sweetser MT, Bakris GL. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20; 389(3):228-238. PMID: 37467498.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    19. Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747. PMID: 37461262; PMCID: PMC10423765.
      Citations: 1     Fields:    Translation:Humans
    20. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Billings LK, Green JB, Koya D, Mosenzon O, Pantalone KM, Ahlers C, Lage A, Lawatscheck R, Scalise A, Bakris GL. The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study. Diabetes Obes Metab. 2023 10; 25(10):2989-2998. PMID: 37402696.
      Citations: 1     Fields:    Translation:Humans
    21. Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, Fonarow GC, Greene SJ, Januzzi JL, Khan MS, Kosiborod MN, McGuire DK, Piña IL, Rosenstock J, Vaduganathan M, Verma S, Zieroth S, Butler J. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol. 2023 06 27; 81(25):2377-2387. PMID: 37344038.
      Citations: 2     Fields:    Translation:Humans
    22. Fletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJL, Jardine MJ, Mahaffey KW, Neal B, Pollock C, Jun M, Rodgers A, Perkovic V, Neuen BL. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 07 04; 12(13):e028516. PMID: 37345834; PMCID: PMC10356084.
      Citations:    Fields:    Translation:Humans
    23. Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DC. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Res Care. 2023 06; 11(3). PMID: 37311602; PMCID: PMC10277062.
      Citations:    Translation:Humans
    24. Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Am J Prev Cardiol. 2023 Jun; 14:100502. PMID: 37313358; PMCID: PMC10258236.
      Citations: 1     
    25. Pitt B, Bakris GL. Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade. Eur Heart J. 2023 May 24. PMID: 37224444.
      Citations:    Fields:    
    26. Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, Arnott C, Hockham C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Mahaffey KW, Perkovic V, Jardine MJ. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023 08; 25(8):2151-2162. PMID: 37161691.
      Citations:    Fields:    Translation:Humans
    27. Heerspink HJL, Jongs N, Neuen BL, Schloemer P, Vaduganathan M, Inker LA, Fletcher RA, Wheeler DC, Bakris G, Greene T, Chertow GM, Perkovic V. Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int. 2023 Jul; 104(1):181-188. PMID: 37119876.
      Citations: 2     Fields:    Translation:Humans
    28. Bansal N, Artinian NT, Bakris G, Chang T, Cohen J, Flythe J, Lea J, Vongpatanasin W, Chertow GM, American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Cardiovascula. Hypertension in Patients Treated With In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement From the American Heart Association. Hypertension. 2023 06; 80(6):e112-e122. PMID: 37092336.
      Citations: 1     Fields:    Translation:Humans
    29. Schlaich MP, Bellet M, Weber MA, Bakris GL, Wang JG, PRECISION investigators. Fluid retention and heart failure in the PRECISION trial - Authors' reply. Lancet. 2023 04 22; 401(10385):1335-1336. PMID: 37087163.
      Citations:    Fields:    Translation:Humans
    30. Bhatt DL, Bakris GL. Key questions regarding the SYMPLICITY HTN-3 trial - Authors' reply. Lancet. 2023 04 22; 401(10385):1337-1338. PMID: 37087166.
      Citations:    Fields:    Translation:Humans
    31. Daugherty A, Lu HS, Bakris GL. Angiotensinogen in Sex and Hypertension: New Insights From the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2023 04 04; 81(13):1260-1262. PMID: 36990545.
      Citations:    Fields:    Translation:Humans
    32. Kahn SE, Anderson CAM, Atkinson MA, Bakris GL, Buse JB, Hu FB, Rich SS, Riddle MC, Selvin E. Reducing Bias in Academic Publishing: The Diabetes Care Approach. Diabetes Care. 2023 04 01; 46(4):665-666. PMID: 36952610.
      Citations:    Fields:    Translation:Humans
    33. Green JB, Bakris G, Heerspink HJL, Mann JFE, McGill JB, Rossing P, Scott C, Gay A, Agarwal R, Mottl AK, Nangaku M. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023 03 31; 38(4):894-903. PMID: 35700142; PMCID: PMC10064838.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    34. Sarafidis P, Agarwal R, Pitt B, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G, FIDELIO-DKD and FIGARO-DKD Investigators, Wanner C, Anker SD. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023 Mar 17. PMID: 36927680; PMCID: PMC10278789.
      Citations: 2     Fields:    
    35. de Zeeuw D, Wheeler DC, CREDENCE Trial Investigators, Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, Heerspink HJL, Neal B, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 Jul; 82(1):84-96.e1. PMID: 36889425.
      Citations:    Fields:    Translation:Humans
    36. McGill JB, Agarwal R, Anker SD, Bakris GL, Filippatos G, Pitt B, Ruilope LM, Caramori ML, Brinker M, Joseph A, Lawatscheck R, Scott C, Rossing P, FIDELIO-DKD and FIGARO-DKD investigators, Birkenfeld AL, Lage A. Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab. 2023 06; 25(6):1512-1522. PMID: 36722675.
      Citations: 1     Fields:    Translation:Humans
    37. Ruilope LM, Pitt B, Rossing P, Kovesdy CP, Pecoits-Filho R, Pergola P, Joseph A, Mentenich N, Scheerer MF, Bakris GL, Anker SD, Lage A. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 02 13; 38(2):372-383. PMID: 35451488; PMCID: PMC9923706.
      Citations: 5     Fields:    Translation:Humans
    38. Blazek O, Bakris GL. Novel Therapies on the Horizon of Hypertension Management. Am J Hypertens. 2023 02 13; 36(2):73-81. PMID: 36201204.
      Citations:    Fields:    Translation:HumansCells
    39. Koshino A, Oshima M, Arnott C, Fletcher RA, Bakris GL, Jardine M, Mahaffey KW, Perkovic V, Pollock C, Heerspink HJL, Neuen BL. Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes Obes Metab. 2023 05; 25(5):1413-1418. PMID: 36655422.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    40. Laffin LJ, Briasoulis A, Bakris GL. Newer alternatives for resistant hypertension: Beyond 2022 paradigms. Hellenic J Cardiol. 2023 Mar-Apr; 70:75-77. PMID: 36739976.
      Citations:    Fields:    Translation:HumansPHPublic Health
    41. Filippatos G, August P, Coats AJS, Januzzi JL, Mankovsky B, Rossing P, Ruilope LM, Pitt B, Teerlink JR, Kapelios CJ, Gebel M, Brinker M, Joseph A, Bakris G, Agarwal R, Anker SD, Sarafidis P, Lage A. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):183-191. PMID: 36639130; PMCID: PMC9892867.
      Citations: 6     Fields:    Translation:Humans
    42. Khan MS, Shahid I, Fonarow GC, Fudim M, Hall ME, Hernandez A, Morris AA, Shafi T, Weir MR, Bakris GL, Butler J, Anker SD, Zannad F. Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 01 24; 81(3):270-282. PMID: 36653095.
      Citations: 2     Fields:    Translation:Humans
    43. Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, Grunberger G, Januzzi JL, Klein S, Kushner PR, McGuire DK, Michos ED, Morales J, Pratley RE, Weir MR, Wright E, Fonseca VA. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023 02; 37(2):108389. PMID: 36669322.
      Citations:    Fields:    Translation:Humans
    44. Filippatos G, Pitt B, McGuire DK, Rossing P, Ruilope LM, Butler J, Jankowska EA, Michos ED, Farmakis D, Farjat AE, Kolkhof P, Scalise A, Joseph A, Bakris GL, Agarwal R, Anker SD. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2022 12 15; 9(1):85-93. PMID: 36251465; PMCID: PMC9753093.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    45. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL, Anker SD. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 02 01; 41(2):295-302. PMID: 36583355; PMCID: PMC9799031.
      Citations: 6     Fields:    Translation:Humans
    46. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 12 01; 45(12):3075-3090. PMID: 36189689; PMCID: PMC9870667.
      Citations: 48     Fields:    Translation:Humans
    47. Rossing P, Filippatos G, Pitt B, Ruilope LM, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R, FIDELIO-DKD and FIGARO-DKD Investigators, Anker SD, Birkenfeld AL. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022 12 01; 45(12):2991-2998. PMID: 35972218; PMCID: PMC9862372.
      Citations: 13     Fields:    Translation:Humans
    48. Rossing P, Garweg JG, Osonoi T, Pitt B, Rosas SE, Ruilope LM, Zhu D, Brinker M, Finis D, Leal S, Schmelter T, Bakris G, Anker SD. Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). Diabetes Obes Metab. 2023 03; 25(3):894-898. PMID: 36331803; PMCID: PMC10100268.
      Citations: 3     Fields:    Translation:Humans
    49. Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG, PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 12 03; 400(10367):1927-1937. PMID: 36356632.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    50. Rossing P, Agarwal R, Filippatos G, Pitt B, Ruilope LM, Fonseca V, Umpierrez GE, Caramori ML, Joseph A, Lambelet M, Lawatscheck R, Bakris GL, FIDELIO-DKD and FIGARO-DKD Investigators, Anker SD. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab. 2023 02; 25(2):407-416. PMID: 36193847; PMCID: PMC10092103.
      Citations: 4     Fields:    Translation:Humans
    51. Sarraju A, Bakris G, Cannon CP, Cherney D, Damaraju CV, Figtree GA, Gogate J, Greene T, Heerspink HJL, Januzzi JL, Neal B, Jardine MJ, Blais J, Kosiborod M, Levin A, Lingvay I, Weir MR, Perkovic V, Mahaffey KW. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731. PMID: 36302584.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    52. Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Malyszko J, Ruilope LM, Rossing P, Pecoits-Filho R, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL, Rossignol P, Anker SD. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023 Feb; 16(2):293-302. PMID: 36864892; PMCID: PMC9972517.
      Citations: 5     
    53. Bakris GL, Filippatos G, Pitt B, Rossing P, Fried L, Roy-Chaudhury P, Sarafidis P, Ahlers C, Brinker M, Joseph A, Lawatscheck R, Agarwal R, FIDELIO-DKD and FIGARO-DKD Investigators, Ruilope LM, Anker SD. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 01; 103(1):196-206. PMID: 36367466.
      Citations: 3     Fields:    Translation:Humans
    54. Khan MS, Ahmed A, Greene SJ, Fiuzat M, Kittleson MM, Butler J, Bakris GL, Fonarow GC. Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. J Card Fail. 2023 01; 29(1):87-107. PMID: 36243339.
      Citations: 1     Fields:    Translation:Humans
    55. Mistry N, Bakris GL. The changing trajectory of diabetic kidney disease. Curr Opin Nephrol Hypertens. 2023 01 01; 32(1):98-102. PMID: 36250469.
      Citations: 1     Fields:    Translation:HumansAnimals
    56. Ruilope LM, Agarwal R, Filippatos G, Pitt B, Rossing P, Sarafidis P, Schmieder RE, Joseph A, Rethemeier N, Nowack C, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 12; 79(12):2685-2695. PMID: 36252131; PMCID: PMC9640256.
      Citations: 6     Fields:    Translation:Humans
    57. Filippatos G, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Agarwal R, Anker SD, Ruilope LM. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Fail. 2022 11; 10(11):860-870. PMID: 36328655.
      Citations: 7     Fields:    Translation:Humans
    58. Bakris GL, Jaisser F. Aldosterone excess and cardiorenal risk: more common than appreciated. Eur Heart J. 2022 10 11; 43(38):3792-3793. PMID: 36219774.
      Citations:    Fields:    Translation:Humans
    59. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 Nov; 102(5):974-989. PMID: 36202661.
      Citations: 14     Fields:    Translation:Humans
    60. Razaghizad A, Sharma A, Ni J, White WB, Mehta CR, Bakris GL, Ferreira JP, Zannad F. External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial. Diabetes Obes Metab. 2023 01; 25(1):229-237. PMID: 36082521.
      Citations:    Fields:    Translation:Humans
    61. Salvador VD, Bakris GL. Novel antihypertensive agents for resistant hypertension: what does the future hold? Hypertens Res. 2022 12; 45(12):1918-1928. PMID: 36167808.
      Citations: 2     Fields:    Translation:Animals
    62. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416. PMID: 36130612.
      Citations: 17     Fields:    Translation:Humans
    63. Kolkhof P, Filippatos G, Bakris GL, Lawatscheck R. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci. 2022 Aug 17; 23(16). PMID: 36012508; PMCID: PMC9408839.
      Citations: 4     Fields:    Translation:Humans
    64. Stergiou G, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, Bakris G, Kollias A, Menti A, Muntner P, Orias M, Poulter N, Shimbo D, Williams B, Adeoye AM, Damasceno A, Korostovtseva L, Li Y, Zhang Y, Mancia G, Tomaszewski M, Brunström M, Muxfeldt E, Kreutz R. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens. 2022 10 01; 40(10):1847-1858. PMID: 35983870.
      Citations: 6     Fields:    Translation:Humans
    65. Smeijer JD, Koomen JV, Kohan DE, McMurray JJV, Bakris GL, Hou FF, Kitzman DW, Makino H, Mayer G, Nowicki M, Perkovic V, Rossing P, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL, Correa-Rotter R. Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease. Clin Pharmacol Ther. 2022 Nov; 112(5):1098-1107. PMID: 35892316.
      Citations: 1     Fields:    Translation:Humans
    66. Li JW, Arnott C, Heerspink HJL, MBiostat QL, Cannon CP, Wheeler DC, Charytan DM, Barraclough J, Figtree GA, Agarwal R, Bakris G, de Zeeuw D, Greene T, Levin A, Pollock C, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Neal B, Jardine MJ. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. J Am Heart Assoc. 2022 08 16; 11(16):e025045. PMID: 35929472; PMCID: PMC9496296.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    67. Toto R, Bakris G. Correction to: The FIDELIO Study Podcast. Diabetes Ther. 2022 Aug; 13(8):1571. PMID: 35780229; PMCID: PMC9309103.
      Citations:    
    68. Iyer NN, Shah S, Ganz ML, Dang-Tan T, Gamble C, Mehanna S, Bakris G, Li Q. Glucose-lowering treatment patterns in patients with diabetic kidney disease. Am J Manag Care. 2022 08 01; 28(8):e301-e307. PMID: 35981131.
      Citations:    Fields:    Translation:Humans
    69. Riddle MC, with and on behalf of Associate Editors Vanita Aroda, Bakris G, Blonde L, Boulton AJM, Castle J, DiMeglio L, Gonder-Frederick L, Hu F, Kahn S, Kaul S, Moses R, Rich S, Rosenstock J, Selvin E, Vella A, Wylie-Rosett J. Editorial Cycles and Continuity of Diabetes Care. Diabetes Care. 2022 07 07; 45(7):1493-1494. PMID: 35796770.
      Citations:    Fields:    Translation:Humans
    70. Bakris G. Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care. J Fam Pract. 2022 07; 71(6 Suppl):S88-S93. PMID: 35960952.
      Citations:    Fields:    Translation:Humans
    71. Agarwal R, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL, Anker SD, Wanner C. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022 06 23; 37(7):1261-1269. PMID: 34850173; PMCID: PMC9217637.
      Citations: 8     Fields:    Translation:Humans
    72. Bakris GL, Weir MR. Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression. Am J Nephrol. 2022; 53(7):513-515. PMID: 35691290.
      Citations: 1     Fields:    Translation:Humans
    73. Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022 08; 102(2):248-260. PMID: 35661785.
      Citations: 34     Fields:    Translation:Humans
    74. Young TK, Toussaint ND, Di Tanna GL, Arnott C, Hockham C, Kang A, Schutte AE, Perkovic V, Mahaffey KW, Agarwal R, Bakris GL, Charytan DM, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Zhang H, Jardine MJ. Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. J Diabetes Res. 2022; 2022:9998891. PMID: 35677742; PMCID: PMC9168808.
      Citations:    Fields:    Translation:Humans
    75. Agarwal R, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A, FIDELIO-DKD and FIGARO-DKD Investigators, Anker SD. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 05 25; 37(6):1014-1023. PMID: 33280027; PMCID: PMC9130026.
      Citations: 24     Fields:    Translation:HumansAnimals
    76. Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, Bauersachs J, Mentz RJ, Kolkhof P, Scott C, Joseph A, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022 06; 24(6):996-1005. PMID: 35239204; PMCID: PMC9541504.
      Citations: 5     Fields:    Translation:Humans
    77. Smeijer JD, Koomen J, Kohan DE, McMurray JJV, Bakris GL, Hou FF, Januzzi JL, Kitzman DW, Kolansky DM, Makino H, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL, Correa-Rotter R. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC Heart Fail. 2022 07; 10(7):498-507. PMID: 35772861.
      Citations: 2     Fields:    Translation:Humans
    78. Khan MS, Bakris GL, Shahid I, Weir MR, Butler J. Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review. JAMA Cardiol. 2022 05 01; 7(5):549-555. PMID: 34985495.
      Citations: 3     Fields:    Translation:Humans
    79. Cohen S, Sternlicht H, Bakris GL. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 05; 22(5):213-218. PMID: 35441935.
      Citations: 1     Fields:    Translation:Humans
    80. Lerma E, White WB, Bakris G. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med. 2023 Apr; 135(3):224-233. PMID: 35392754.
      Citations: 3     Fields:    Translation:Humans
    81. DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022 07; 24(7):1197-1205. PMID: 35302284; PMCID: PMC9323420.
      Citations: 6     Fields:    Translation:Humans
    82. Khan MS, Bakris GL, Packer M, Shahid I, Fonarow GC, Weir MR, Butler J, Anker SD, Wanner C, Zannad F. Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J. 2022 04 06; 43(14):1379-1400. PMID: 34966917.
      Citations: 3     Fields:    Translation:Humans
    83. Rossing P, Burgess E, Agarwal R, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 04 01; 45(4):888-897. PMID: 35061867; PMCID: PMC9271031.
      Citations: 5     Fields:    Translation:Humans
    84. Toto R, Bakris G. The FIDELIO Study Podcast. Diabetes Ther. 2022 May; 13(5):823-828. PMID: 35325360; PMCID: PMC9076781.
      Citations:    
    85. Chiu N, Aggarwal R, Bakris GL, Pitt B, Bhatt DL. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 04 05; 11(7):e025079. PMID: 35311349; PMCID: PMC9075441.
      Citations: 2     Fields:    Translation:Humans
    86. van Kleef MEAM, Devireddy CM, van der Heyden J, Bates MC, Bakris GL, Stone GW, Williams B, Spiering W, CALM-FIM Investigators. Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 02 14; 15(3):321-332. PMID: 35144789.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    87. Liao J, Kang A, Xia C, Young T, Di Tanna GL, Arnott C, Pollock C, Krishnan AV, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Levin A, Neal B, Wheeler DC, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Jardine MJ, Smyth B. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes Metab. 2022 07; 48(4):101331. PMID: 35172198.
      Citations: 2     Fields:    Translation:Humans
    88. Agarwal R, Filippatos G, Pitt B, Rossing P, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators, Anker SD, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10; 43(6):474-484. PMID: 35023547; PMCID: PMC8830527.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    89. Yu J, Jardine MJ, Cannon CP, Agarwal R, Bakris G, Greene T, Levin A, Pollock C, Powe NR, Arnott C, CREDENCE study investigators, Charytan DM, Mahaffey KW. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 03; 17(3):361-373. PMID: 35063969; PMCID: PMC8975029.
      Citations:    Fields:    Translation:Humans
    90. Stavas J, Gerber D, Coca SG, Silva AL, Johns A, Jain D, Bertram T, Bakris G, Díaz-González de Ferris M. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58. PMID: 35034024.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    91. Salvador VD, Bakris GL. Identifying Resistant Hypertension in the Population: The Devil Is in the Details. Can J Cardiol. 2022 05; 38(5):555-556. PMID: 35033633.
      Citations:    Fields:    Translation:Humans
    92. Bakris GL, Kolkhof P, Kintscher U. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022 07; 179(13):3220-3234. PMID: 34811750.
      Citations: 22     Fields:    Translation:Humans
    93. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S185-S194. PMID: 34964887.
      Citations: 42     Fields:    Translation:Humans
    94. American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S244-S253. PMID: 34964884.
      Citations: 54     Fields:    Translation:Humans
    95. American Diabetes Association Professional Practice Committee. Summary of Revisions: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S4-S7. PMID: 34964881.
      Citations: 13     Fields:    
    96. American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S39-S45. PMID: 34964876.
      Citations: 30     Fields:    Translation:Humans
    97. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S17-S38. PMID: 34964875.
      Citations: 455     Fields:    Translation:Humans
    98. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S175-S184. PMID: 34964873.
      Citations: 83     Fields:    Translation:Humans
    99. American Diabetes Association Professional Practice Committee. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S8-S16. PMID: 34964872.
      Citations: 24     Fields:    Translation:Humans
    100. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S97-S112. PMID: 34964871.
      Citations: 64     Fields:    Translation:Humans
    101. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S46-S59. PMID: 34964869; PMCID: PMC8935396.
      Citations: 47     Fields:    Translation:Humans
    102. American Diabetes Association Professional Practice Committee. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S83-S96. PMID: 34964868.
      Citations: 149     Fields:    Translation:Humans
    103. American Diabetes Association Professional Practice Committee. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S60-S82. PMID: 34964866.
      Citations: 80     Fields:    Translation:Humans
    104. American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S208-S231. PMID: 34964865.
      Citations: 48     Fields:    Translation:Humans
    105. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S232-S243. PMID: 34964864.
      Citations: 49     Fields:    Translation:Humans
    106. American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S195-S207. PMID: 34964847; PMCID: PMC8935395.
      Citations: 46     Fields:    Translation:Humans
    107. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S113-S124. PMID: 34964843.
      Citations: 50     Fields:    Translation:Humans
    108. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S125-S143. PMID: 34964831.
      Citations: 251     Fields:    Translation:Humans
    109. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S144-S174. PMID: 34964815.
      Citations: 111     Fields:    Translation:Humans
    110. Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL, Górriz JL. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 12 21; 42(48):4891-4901. PMID: 34423370.
      Citations: 29     Fields:    Translation:Humans
    111. Shaman AM, Bain SC, Bakris GL, Buse JB, Mahaffey KW, Mann JFE, Rossing P, Zinman B, Perkovic V, Idorn T, Nauck MA, Rasmussen S, Wolthers B. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585. PMID: 34903039; PMCID: PMC8860212.
      Citations: 30     Fields:    Translation:Humans
    112. Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101. PMID: 34922811.
      Citations: 5     Fields:    Translation:Humans
    113. Bakris G, Mehta C, White WB, Ferreira JP, Rossignol P, Zannad F. Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. Am J Nephrol. 2021; 52(12):969-976. PMID: 34872085.
      Citations: 1     Fields:    Translation:Humans
    114. Waijer SW, Gansevoort RT, Bakris GL, Hou FF, Kohan DE, Kitzman DW, Makino H, McMurray JJV, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL, Correa-Rotter R. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 12; 16(12):1824-1832. PMID: 34853062; PMCID: PMC8729501.
      Citations: 4     Fields:    Translation:Humans
    115. Filippatos G, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Pitt B, FIGARO-DKD Investigators, Anker SD, Lage A. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 02 08; 145(6):437-447. PMID: 34775784; PMCID: PMC8812430.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    116. Agarwal R, Joseph A, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237. PMID: 34732509; PMCID: PMC8763180.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    117. Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nishiyama A, Node K, Bakris G, Miura K, Muntner P, Viera AJ, Oparil S, Lloyd-Jones DM, Yasunaga H, Komuro I. Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. J Am Heart Assoc. 2021 11 16; 10(22):e022479. PMID: 34724797; PMCID: PMC8751953.
      Citations: 3     Fields:    Translation:Humans
    118. Bakris GL, Barrera-Chimal J, Lima-Posada I, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70. PMID: 34675379.
      Citations: 29     Fields:    Translation:Humans
    119. Pitt B, Jaisser F, Bakris G. An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. Expert Opin Investig Drugs. 2021 Oct; 30(10):1017-1023. PMID: 34595995.
      Citations: 4     Fields:    Translation:Humans
    120. Rossing P, Filippatos G, Agarwal R, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, Joseph A, Scheerer MF, Scott C, Bakris GL, FIDELIO-DKD Investigators, Anker SD, Wanner C. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2022 Jan; 7(1):36-45. PMID: 35005312; PMCID: PMC8720648.
      Citations: 23     
    121. Salvador VD, Bakris GL. Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm. Hypertension. 2021 11; 78(5):1365-1367. PMID: 34644175.
      Citations:    Fields:    Translation:Humans
    122. Rossing P, Agarwal R, Filippatos G, Pitt B, Ruilope LM, Amod A, Joseph A, Scott C, Bakris GL, FIDELIO-DKD Investigators, Anker SD, Marre M, Lage A. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab. 2022 01; 24(1):125-134. PMID: 34580995; PMCID: PMC9293162.
      Citations: 21     Fields:    Translation:Humans
    123. Zemke AM, Rodby RA, Hertl M, Waleed A, Bakris GL. Successful treatment of refractory hypertension with bilateral nephrectomy in a patient with chronic kidney disease stage 3. Clin Kidney J. 2022 Feb; 15(2):347-350. PMID: 35145649; PMCID: PMC8824767.
      Citations:    
    124. Heerspink HJL, Xie D, Bakris G, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Perkovic V, Rossing P, Parving HH, de Zeeuw D, on behalf on the SONAR Investigators, Correa-Rotter R. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911. PMID: 34551995; PMCID: PMC8806086.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    125. Bakris G, Mehta C, White WB, Ferreira JP, Rossignol P, Zannad F. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187. PMID: 34521390; PMCID: PMC8442423.
      Citations: 1     Fields:    Translation:Humans
    126. Filippatos G, Agarwal R, Bakris G, FIDELIO-DKD Committees and Investigators, Anker S. Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". Circulation. 2021 09 14; 144(11):e202-e203. PMID: 34516303.
      Citations:    Fields:    Translation:Humans
    127. FIGARO-DKD Investigators, Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 12 09; 385(24):2252-2263. PMID: 34449181.
      Citations: 213     Fields:    Translation:HumansCTClinical Trials
    128. Kandzari DE, Townsend RR, Bakris G, Basile J, Bloch MJ, Cohen DL, East C, Ferdinand KC, Fisher N, Kirtane A, Lee DP, Puckrein G, Rader F, Vassalotti JA, Weber MA, Willis K, Secemsky E. Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 09; 98(3):416-426. PMID: 34343406.
      Citations: 10     Fields:    Translation:Humans
    129. Laffin LJ, Bakris GL. Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy. Cardiol Clin. 2021 Aug; 39(3):377-387. PMID: 34247751.
      Citations:    Fields:    Translation:Humans
    130. Laffin LJ, Bakris GL. Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Curr Cardiol Rep. 2021 07 16; 23(9):117. PMID: 34269921.
      Citations: 7     Fields:    Translation:Humans
    131. Al Dhaybi O, Bakris GL. Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents. Adv Chronic Kidney Dis. 2021 07; 28(4):371-377. PMID: 34922693.
      Citations: 1     Fields:    Translation:Humans
    132. Bakris GL, Mikami H, Hirata M, Nakajima A, Cressman MD. A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360. 2021 08 26; 2(8):1240-1250. PMID: 35369650; PMCID: PMC8676384.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    133. Pulipati VP, Mares JW, Bakris GL. Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications. Am J Med. 2021 10; 134(10):1195-1198. PMID: 34197786.
      Citations:    Fields:    Translation:Humans
    134. Brook RD, Kaciroti N, Bakris G, Pitt B, Velazquez E, Weber MA, Jamerson KA, Dahlöf B. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539. PMID: 33216879.
      Citations: 1     Fields:    Translation:Humans
    135. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, Butler J, Lam CSP, Kolkhof P, Roberts L, Tasto C, Joseph A, FIDELIO-DKD Investigators, Anker SD. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 07 13; 78(2):142-152. PMID: 34015478.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    136. Polonsky TS, Bakris GL. Systolic Blood Pressure During Exercise Testing: Where the Valley Means More Than the Peak. Hypertension. 2021 06; 77(6):1915-1917. PMID: 33979181.
      Citations:    Fields:    
    137. Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B, BLOCK-CKD Study Group. Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021 07; 78(1):74-81. PMID: 33966452; PMCID: PMC8189259.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    138. Morgan ES, Tami Y, Hu K, Brambatti M, Mullick AE, Geary RS, Bakris GL, Tsimikas S. Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies. JACC Basic Transl Sci. 2021 Jun; 6(6):485-496. PMID: 34222719; PMCID: PMC8246029.
      Citations: 8     
    139. Rossello X, Caimari F, Sharma A, Mehta C, Bakris G, Cannon CP, White WB, Ferreira JP, Lamiral Z, Zannad F. Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol. 2021 Oct; 110(10):1612-1624. PMID: 33929598.
      Citations: 5     Fields:    Translation:Humans
    140. Arnott C, Li JW, Cannon CP, de Zeeuw D, Neuen BL, Heerspink HJL, Charytan DM, Agarwal A, Huffman MD, Figtree GA, Bakris G, Chang TI, Feng K, Rosenthal N, Zinman B, Jardine MJ, Perkovic V, Neal B, Mahaffey KW. The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes Obes Metab. 2021 07; 23(7):1652-1659. PMID: 33769679.
      Citations: 2     Fields:    Translation:Humans
    141. Bakris G, Mehta C, White WB, Ferreira JP, Lamiral Z, Zannad F. Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. Diabetes Obes Metab. 2021 07; 23(7):1580-1587. PMID: 33687751.
      Citations: 9     Fields:    Translation:HumansCells
    142. Bakris GL, Agarwal R, Filippatos G, FIDELIO-DKD Study Group. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2021 03 18; 384(11):e42. PMID: 33730470.
      Citations: 2     Fields:    Translation:Humans
    143. Bakris G, Sternlicht H. Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control. J Am Coll Cardiol. 2021 03 16; 77(10):1300-1301. PMID: 33706871; PMCID: PMC8091295.
      Citations: 4     Fields:    Translation:Humans
    144. Bakris GL, Woods SD, Alvarez PJ, Arthur SP, Kumar R. Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial. Kidney Med. 2021 May-Jun; 3(3):360-367.e1. PMID: 34136782; PMCID: PMC8178474.
      Citations: 1     
    145. Jardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R, Bakris GL, Cannon CP, Charytan DM, Greene T, Levin A, Li JW, Neuen BL, Neal B, Oh R, Oshima M, Pollock C, Wheeler DC, de Zeeuw D, Zhang H, Zinman B, Mahaffey KW, Perkovic V. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395. PMID: 33619120; PMCID: PMC8011002.
      Citations: 15     Fields:    Translation:Humans
    146. Prischl FC, Rossing P, Bakris G, Mayer G, Wanner C. Major adverse renal events (MARE): a proposal to unify renal endpoints. Nephrol Dial Transplant. 2021 02 20; 36(3):491-497. PMID: 31711188.
      Citations: 7     Fields:    Translation:Humans
    147. Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, Bakris G, Schutte AE, Arnott C, Chang TI, Cannon CP, Charytan DM, de Zeeuw D, Levin A, Mahaffey KW, Neal B, Pollock C, Wheeler DC, Luca Di Tanna G, Cheng H, Perkovic V, Neuen BL, Górriz JL. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Circulation. 2021 05 04; 143(18):1735-1749. PMID: 33554616.
      Citations: 19     Fields:    Translation:Humans
    148. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 01 07; 42(2):152-161. PMID: 33099609; PMCID: PMC7813624.
      Citations: 89     Fields:    Translation:Humans
    149. Koomen JV, Stevens J, Bakris G, Hou FF, Kitzman DW, Kohan DE, Makino H, McMurray JJV, Parving HH, Perkovic V, Tobe SW, de Zeeuw D, Heerspink HJL, Correa-Rotter R. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638. PMID: 33338269; PMCID: PMC8246733.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    150. Riddle MC, Bakris G, Blonde L, Boulton AJM, D'Alessio D, DiMeglio LA, Gonder-Frederick L, Hood KK, Hu FB, Kahn SE, Kaul S, Leiter LA, Moses RG, Rich SS, Rosenstock J, Wylie-Rosett J. A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care. 2021 01; 44(1):8-10. PMID: 33571952.
      Citations: 2     Fields:    
    151. Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148. PMID: 33358942.
      Citations: 14     Fields:    Translation:Humans
    152. Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP, Chickering JG, Chien YT, Carlson K, Cressman MD, Currie MG, Milne GT, Profy AT. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69. PMID: 33328269; PMCID: PMC7792638.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    153. Aggarwal R, Lu K, Chiu N, Bakris GL, Bhatt DL. U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. J Am Coll Cardiol. 2020 12 15; 76(24):2907-2910. PMID: 33303081.
      Citations: 1     Fields:    Translation:Humans
    154. Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Lim SK, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Perkovic V, Heerspink HJL. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021 04; 99(4):999-1009. PMID: 33316282.
      Citations: 27     Fields:    Translation:Humans
    155. Koomen JV, Stevens J, Bakris G, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Parving HH, Perkovic V, Tobe SW, de Zeeuw D, Heerspink HJL, Correa-Rotter R. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes Obes Metab. 2021 02; 23(2):561-568. PMID: 33184931; PMCID: PMC7839558.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    156. Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V, Bakris G. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714. PMID: 33214158; PMCID: PMC7769025.
      Citations: 39     Fields:    Translation:Humans
    157. Filippatos G, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 02 09; 143(6):540-552. PMID: 33198491; PMCID: PMC7864612.
      Citations: 79     Fields:    Translation:HumansCTClinical Trials
    158. Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, Zinman B, Inzucchi SE, Kraus BJ, von Eynatten M, Wanner C, Koitka-Weber A. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762. PMID: 33181154.
      Citations: 37     Fields:    Translation:Humans
    159. Itano S, Yano Y, Nagasu H, Tomiyama H, Kanegae H, Makino H, Higashi Y, Kobayashi Y, Sogawa Y, Satoh M, Suzuki K, Townsend RR, Budoff M, Bakris G, Kashihara N. Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. Am J Hypertens. 2020 11 03; 33(11):1003-1010. PMID: 32530466; PMCID: PMC7750955.
      Citations: 4     Fields:    Translation:Humans
    160. Oshima M, Neuen BL, Jardine MJ, Bakris G, Edwards R, Levin A, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wada T, Wheeler DC, Perkovic V, Heerspink HJL. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020 11; 8(11):903-914. PMID: 33065060.
      Citations: 29     Fields:    Translation:Humans
    161. Ali W, Nathan S, Funaki B, Eggener S, Bakris G. An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. JACC Case Rep. 2020 Dec; 2(15):2460-2464. PMID: 34317194; PMCID: PMC8304536.
      Citations:    
    162. FIDELIO-DKD Investigators, Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229. PMID: 33264825.
      Citations: 419     Fields:    Translation:HumansCTClinical Trials
    163. Ali W, Bakris GL. How to Manage Hypertension in People With Diabetes. Am J Hypertens. 2020 10 21; 33(10):935-943. PMID: 32307510.
      Citations: 1     Fields:    Translation:Humans
    164. Bakris G. Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician. J Fam Pract. 2020 09; 69(7 Suppl):S81-S86. PMID: 33104113.
      Citations:    Fields:    Translation:Humans
    165. Sharma A, Mehta C, Bakris G, White WB, Ferreira JP, Rossignol P, Zannad F. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2021 Jul; 110(7):1006-1019. PMID: 32789678.
      Citations: 10     Fields:    Translation:Humans
    166. Elharram M, Sharma A, White W, Bakris G, Mehta C, Rossignol P, Ferreira JP, Zannad F. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020 11; 229:40-51. PMID: 32916607.
      Citations: 1     Fields:    Translation:Humans
    167. Sarafidis P, Bakris G. Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It? Diabetes Care. 2020 08; 43(8):1684-1686. PMID: 32669408.
      Citations: 1     Fields:    Translation:Humans
    168. Ali W, Bakris G. Evolution of Patiromer Use: a Review. Curr Cardiol Rep. 2020 07 09; 22(9):94. PMID: 32648072.
      Citations: 5     Fields:    Translation:Humans
    169. Sternlicht HK, Bakris GL. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555. PMID: 32559465.
      Citations: 2     Fields:    Translation:Humans
    170. Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Bikos A, Raptis V, Syrgkanis C, Liakopoulos V, Papagianni A, Bakris G, Parati G. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2020 07 01; 35(7):1277. PMID: 30239875.
      Citations: 1     Fields:    
    171. Bakris G, Yang YF, Pitt B. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149. PMID: 32520623.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    172. Butler J, Pitt B, Kosiborod M, Lund LH, Bakris GL, Weir MR, Ferreira JP, Rossignol P, Anker SD, Zannad F. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 06 09; 75(22):2836-2850. PMID: 32498812.
      Citations: 39     Fields:    Translation:Humans
    173. Al Dhaybi O, Bakris GL. Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference. Clin Kidney J. 2021 Mar; 14(3):1023-1024. PMID: 34840734; PMCID: PMC8612138.
      Citations:    
    174. Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V, CREDENCE Study Investigators. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139. PMID: 32354987; PMCID: PMC7217416.
      Citations: 49     Fields:    Translation:Humans
    175. Al Dhaybi O, Bakris GL. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab. 2020 04; 22 Suppl 1:69-76. PMID: 32267074.
      Citations: 6     Fields:    Translation:Humans
    176. Bakris GL, Josephson MA. Improvement of Cardiovascular Functional Reserve After Kidney Transplant-Has the CAPER Been Solved? JAMA Cardiol. 2020 04 01; 5(4):430-431. PMID: 32022826.
      Citations:    Fields:    Translation:HumansAnimals
    177. Ali WE, Bakris GL. Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance. Hypertension. 2020 04; 75(4):943-944. PMID: 32148130.
      Citations:    Fields:    Translation:Humans
    178. Idzerda NMA, Clegg LE, Hernandez AF, Bakris G, Penland RC, Boulton DW, Bethel MA, Holman RR, Heerspink HJL. Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obes Metab. 2020 05; 22(5):798-806. PMID: 31912603; PMCID: PMC7187441.
      Citations: 8     Fields:    Translation:Humans
    179. Ali W, Gao G, Bakris GL. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254. PMID: 31982868.
      Citations: 2     Fields:    Translation:Humans
    180. Butler J, Handelsman Y, Bakris G, Verma S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617. PMID: 31926059.
      Citations: 17     Fields:    Translation:Humans
    181. Vaduganathan M, Liu Y, Bakris GL, Cannon CP, White WB, Sharma A, Ferreira JP, Zannad F. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797. PMID: 31902327; PMCID: PMC6988143.
      Citations: 9     Fields:    Translation:Humans
    182. Polonsky TS, Bakris GL. Paradoxical Cardiorenal Responses Following Acute Vasodilator/Natriuretic Treatment in Presystolic Heart Failure: Should We Be Surprised? JACC Basic Transl Sci. 2019 Dec; 4(8):973-975. PMID: 31909769; PMCID: PMC6938987.
      Citations:    
    183. Alexandrou ME, Papagianni A, Tsapas A, Loutradis C, Boutou A, Piperidou A, Papadopoulou D, Ruilope L, Bakris G, Sarafidis P. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019 12; 37(12):2307-2324. PMID: 31688290.
      Citations: 27     Fields:    Translation:Humans
    184. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452. PMID: 31757838; PMCID: PMC7411285.
      Citations: 30     Fields:    Translation:Humans
    185. Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410. PMID: 31707795.
      Citations: 38     Fields:    Translation:Humans
    186. Ruilope LM, Agarwal R, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B, Anker SD, FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356. PMID: 31665733; PMCID: PMC6889917.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    187. Bakris GL, Agarwal R, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Schloemer P, Filippatos G, Anker SD, Ferreira AC, on behalf of the FIDELIO-DKD study investigators, FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344. PMID: 31655812; PMCID: PMC6888890.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    188. Koyner J, Bakris G. Kidney injury is not prevented by hydration alone. Eur Heart J. 2019 10 07; 40(38):3179-3181. PMID: 31263876.
      Citations:    Fields:    Translation:Humans
    189. Baliga RR, Bossone E, Bakris GL. Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage. Heart Fail Clin. 2019 10; 15(4):xiii-xv. PMID: 31472892.
      Citations:    Fields:    
    190. Bakris G. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. J Fam Pract. 2019 10; 68(8):S1-S6. PMID: 31697796.
      Citations:    Fields:    Translation:Humans
    191. Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR, Murad MH, Rosenzweig JL, Vergès BL. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 Sep 01; 104(9):3939-3985. PMID: 31365087.
      Citations: 17     Fields:    
    192. Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019 08; 37(8):1574-1586. PMID: 30882593; PMCID: PMC6615933.
      Citations: 20     Fields:    Translation:Humans
    193. Polonsky TS, Bakris GL. Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting. Heart Fail Clin. 2019 Oct; 15(4):455-461. PMID: 31472881.
      Citations: 3     Fields:    Translation:Humans
    194. Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 08 27; 140(9):739-750. PMID: 31291786; PMCID: PMC6727954.
      Citations: 88     Fields:    Translation:HumansPHPublic Health
    195. Bakris GL. Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. Am J Kidney Dis. 2019 11; 74(5):573-575. PMID: 31262591.
      Citations: 6     Fields:    Translation:Humans
    196. Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019 06 18; 73(23):3018-3026. PMID: 31196460.
      Citations: 79     Fields:    Translation:Humans
    197. Bakris GL, Laffin LJ. Assessing Wide Pulse Pressure Hypertension: Data Beyond the Guidelines. J Am Coll Cardiol. 2019 06 11; 73(22):2856-2858. PMID: 31171091; PMCID: PMC7111461.
      Citations: 6     Fields:    Translation:Humans
    198. Ali W, Bakris G. The Management of Hypertension in 2018: What Should the Targets Be? Curr Hypertens Rep. 2019 04 25; 21(6):41. PMID: 31025203.
      Citations: 6     Fields:    Translation:Humans
    199. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306. PMID: 30990260.
      Citations: 1529     Fields:    Translation:Humans
    200. Heerspink HJL, Parving HH, Andress DL, Bakris G, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D, SONAR Committees and Investigators, Correa-Rotter R. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947. PMID: 30995972.
      Citations: 182     Fields:    Translation:Humans
    201. Bakris G. Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019 03 29; 124(7):969-971. PMID: 30920926.
      Citations: 3     Fields:    Translation:Humans
    202. Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Bikos A, Raptis V, Syrgkanis C, Liakopoulos V, Papagianni A, Bakris G, Parati G. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2019 03 01; 34(3):515-523. PMID: 30184172.
      Citations: 12     Fields:    Translation:Humans
    203. Vijayakumar S, Butler J, Bakris GL. Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. Eur Heart J Suppl. 2019 Feb; 21(Suppl A):A20-A27. PMID: 30837801; PMCID: PMC6392419.
      Citations: 4     
    204. Sternlicht H, Bakris GL. Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Curr Hypertens Rep. 2019 02 12; 21(2):12. PMID: 30747296.
      Citations: 16     Fields:    Translation:Humans
    205. Ihm SH, Bakris G, Sakuma I, Sohn IS, Koh KK. Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines? - An Asian Perspective. Circ J. 2019 02 25; 83(3):504-510. PMID: 30606943.
      Citations: 10     Fields:    Translation:Humans
    206. Parati G, Agabiti-Rosei E, Bakris GL, Bilo G, Branzi G, Chrostowska M, De la Sierra A, Dorobantu M, Faria T, Huo Y, Jelakovic B, Kahan T, Konradi A, Li N, Madan K, Mancia G, McManus RJ, Modesti PA, Ochoa JE, Omboni S, Palatini P, Park JB, Pellegrini D, Perl S, Podoleanu C, Pucci G, Redon J, Rhee MY, Rodilla Sala E, Sanchez R, Schmieder R, Soranna D, Stergiou G, Stojanovic M, Tsioufis K, Valsecchi MG, Waisman GD, Wang JG, Wijnmaalen P, Zambon A, Zanchetti A, Zhang Y, Cecchi F, Domenech M, Laurent S, Octavio JA, Renna N, Veglio F. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open. 2018 12 19; 8(12):e021038. PMID: 30573476; PMCID: PMC6303603.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    207. Bakris GL, Agarwal R. Creatinine Bump Following Antihypertensive Therapy. Hypertension. 2018 12; 72(6):1274-1276. PMID: 30571245.
      Citations: 2     Fields:    Translation:Humans
    208. Hammes M, Bakris GL. Intradialytic Hypotension: Is Midodrine the Answer? Am J Nephrol. 2018; 48(5):378-380. PMID: 30423560.
      Citations: 1     Fields:    Translation:Humans
    209. Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Cannon CP, Bakris GL, EXAMINE Investigators, Zannad F. Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). Am J Cardiol. 2019 02 01; 123(3):382-391. PMID: 30477800.
      Citations: 5     Fields:    Translation:Humans
    210. Polonsky TS, Bakris GL. Ambulatory Blood Pressure Monitoring. JAMA. 2018 Nov 06; 320(17):1807-1808. PMID: 30398582.
      Citations: 2     Fields:    Translation:Humans
    211. de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933. PMID: 30413396.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    212. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB, American Heart Association Professional/Public Education and Publications Committee of the Council o. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90. PMID: 30354828; PMCID: PMC6530990.
      Citations: 255     Fields:    Translation:Humans
    213. Ali WE, Bakris GL. Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used. Eur Heart J. 2018 10 21; 39(40):3662-3663. PMID: 30137271.
      Citations:    Fields:    Translation:Humans
    214. White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Cannon CP, Zannad F. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114. PMID: 30371278; PMCID: PMC6474950.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    215. Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550. PMID: 29941478; PMCID: PMC6181277.
      Citations: 91     Fields:    Translation:Humans
    216. Laffin LJ, Bakris GL. Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension? Hypertension. 2018 10; 72(4):836-838. PMID: 30354732; PMCID: PMC6289950.
      Citations: 1     Fields:    Translation:Humans
    217. Schlaich MP, Bakris GL. Renal denervation: one step backwards, three steps forward. Nat Rev Nephrol. 2018 10; 14(10):602-604. PMID: 29980772.
      Citations: 1     Fields:    Translation:Humans
    218. Bakris GL, Polonsky TS. Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. J Am Coll Cardiol. 2018 09 11; 72(11):1224-1226. PMID: 30189999.
      Citations:    Fields:    Translation:Humans
    219. Bakris G, Sorrentino M. Perspective on the New Blood-Pressure Guidelines. Eur Heart J. 2018 Sep 01; 39(33):3008-3009. PMID: 30990868.
      Citations:    Fields:    
    220. Ferdinand KC, Bakris GL, Cushman WC, Weber MA, Lloyd E, Wu J, White WB. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018 11 01; 122(9):1496-1505. PMID: 30217371.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    221. K Dojki F, Bakris GL. Hyperkalaemia in diabetes: a silent risk predicting poor outcomes. Diabet Med. 2018 08; 35(8):1049-1050. PMID: 29790205.
      Citations:    Fields:    Translation:Humans
    222. Riddle MC, Bakris G, Boulton AJM, Blonde L, D'Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L. Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care. 2018 07; 41(7):1327-1329. PMID: 29934474.
      Citations:    Fields:    
    223. Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602. PMID: 29767459; PMCID: PMC6073017.
      Citations: 15     Fields:    Translation:CTClinical Trials
    224. Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Sharma A, Zannad F. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11). PMID: 29769203; PMCID: PMC6015373.
      Citations: 3     Fields:    Translation:Humans
    225. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D, Correa-Rotter R. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835. PMID: 29604160; PMCID: PMC6055730.
      Citations: 14     Fields:    Translation:Humans
    226. de Boer IH, Bakris G, Cannon CP. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 03; 319(13):1319-1320. PMID: 29543954.
      Citations: 12     Fields:    Translation:Humans
    227. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 04; 36(4):947-956. PMID: 29334491; PMCID: PMC5862000.
      Citations: 3     Fields:    Translation:Humans
    228. de Boer IH, Bakris GL. Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care. 2018 04; 41(4):662-663. PMID: 29559452; PMCID: PMC6463621.
      Citations: 8     Fields:    Translation:Humans
    229. Omboni S, Kario K, Bakris G, Parati G. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733. PMID: 29045341; PMCID: PMC5862001.
      Citations: 9     Fields:    Translation:Humans
    230. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK, Cífková R. Hypertension. Nat Rev Dis Primers. 2018 03 22; 4:18014. PMID: 29565029; PMCID: PMC6477925.
      Citations: 297     Fields:    Translation:Humans
    231. Al Dhaybi O, Bakris GL. Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. J Clin Hypertens (Greenwich). 2018 04; 20(4):625-626. PMID: 29532984; PMCID: PMC8031035.
      Citations: 1     Fields:    Translation:Humans
    232. Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. J Am Coll Cardiol. 2018 03 27; 71(12):1379-1390. PMID: 29534825; PMCID: PMC5832063.
      Citations: 17     Fields:    Translation:Humans
    233. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D, Correa-Rotter R. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376. PMID: 29405626; PMCID: PMC5969254.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    234. Bakris GL, Zhao L, Kupfer S, Juhasz A, Hisada M, Lloyd E, Oparil S. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 04; 20(4):694-702. PMID: 29504252; PMCID: PMC8031057.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    235. Bakris GL, Molitch M. Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. Diabetes Care. 2018 03; 41(3):389-390. PMID: 29463664.
      Citations: 11     Fields:    Translation:Humans
    236. Dojki FK, Bakris GL. Blood Pressure Control and Cardiovascular/Renal Outcomes. Endocrinol Metab Clin North Am. 2018 03; 47(1):175-184. PMID: 29407050.
      Citations: 4     Fields:    Translation:Humans
    237. Laffin LJ, Bakris GL. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. Diabetes Obes Metab. 2018 06; 20(6):1335-1336. PMID: 29424470; PMCID: PMC5948152.
      Citations: 1     Fields:    Translation:Humans
    238. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Stahl E, Weiner DE, Chertow GM, Sanchez Lozada LG. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018 06; 71(6):851-865. PMID: 29496260; PMCID: PMC7286363.
      Citations: 162     Fields:    Translation:Humans
    239. Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 01 19; 20(1):1. PMID: 29349558.
      Citations: 24     Fields:    Translation:Humans
    240. Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47. PMID: 29402767; PMCID: PMC5841134.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    241. Bakris G, Sorrentino M. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018 02 08; 378(6):497-499. PMID: 29341841.
      Citations: 35     Fields:    Translation:Humans
    242. White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM, Garlo KG. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 03 07; 13(3):398-405. PMID: 29339356; PMCID: PMC5967667.
      Citations: 14     Fields:    Translation:Humans
    243. Plutzky J, Bakris G. Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133. PMID: 29311346.
      Citations: 2     Fields:    Translation:Humans
    244. Brook RD, Kaciroti N, Bakris G, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA, Dahlöf B. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1). PMID: 29301757; PMCID: PMC5778960.
      Citations: 3     Fields:    Translation:Humans
    245. Bakris GL. Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes. Kidney Int Suppl (2011). 2018 Jan; 8(1):1. PMID: 30675432; PMCID: PMC6336218.
      Citations: 2     
    246. Cherney DZI, Bakris GL. Novel therapies for diabetic kidney disease. Kidney Int Suppl (2011). 2018 Jan; 8(1):18-25. PMID: 30675435; PMCID: PMC6336219.
      Citations: 15     
    247. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V, CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13; 46(6):462-472. PMID: 29253846; PMCID: PMC5804835.
      Citations: 79     Fields:    
    248. Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Am J Med. 2018 05; 131(5):555-564.e3. PMID: 29180023.
      Citations: 22     Fields:    Translation:Humans
    249. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659. PMID: 29064626; PMCID: PMC5836896.
      Citations: 16     Fields:    Translation:Humans
    250. Al Dhabyi O, Bakris GL. Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People? J Am Heart Assoc. 2017 11 18; 6(11). PMID: 29151038; PMCID: PMC5721807.
      Citations: 1     Fields:    Translation:Humans
    251. Yamout H, Bakris GL. Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension. Clin J Am Soc Nephrol. 2018 01 06; 13(1):9-10. PMID: 29101187; PMCID: PMC5753324.
      Citations: 4     Fields:    Translation:Humans
    252. Deedwania P, Weber M, Reimitz PE, Bakris G. Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1309-1318. PMID: 29067756; PMCID: PMC5765479.
      Citations: 2     Fields:    Translation:Humans
    253. Bakris GL. MY APPROACH to the elderly patient with resistant hypertension. Trends Cardiovasc Med. 2018 01; 28(1):79-80. PMID: 29032932.
      Citations:    Fields:    Translation:Humans
    254. de Boer IH, Bangalore S, Davis AM, Michos ED, Muntner P, Rossing P, Zoungas S, Bakris G, Benetos A. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 09; 40(9):1273-1284. PMID: 28830958.
      Citations: 189     Fields:    
    255. Dojki FK, Bakris G. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374. PMID: 28771453.
      Citations: 11     Fields:    Translation:Humans
    256. Laffin LJ, Bakris GL. Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846. PMID: 27838622; PMCID: PMC6279104.
      Citations: 2     Fields:    Translation:Humans
    257. Ai Dhaybi O, Bakris GL. Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. Clin Pharmacol Ther. 2017 Sep; 102(3):450-458. PMID: 28589612.
      Citations: 3     Fields:    Translation:HumansAnimals
    258. Waksman R, Bakris GL, Steinvil A, Garcia-Garcia H, Brown AL, DiFilippo W, Scott T, Singh J, DeBruin V, Jones D, Jolivette D, Bhatt DL. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84. PMID: 28938966.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    259. Laffin LJ, Jafar MS, Bakris GL. Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. J Clin Hypertens (Greenwich). 2017 Nov; 19(11):1202-1203. PMID: 28646567; PMCID: PMC5745160.
      Citations: 1     Fields:    Translation:Humans
    260. Johnson W, White WB, Sica D, Bakris GL, Weber MA, Handley A, Perez A, Cao C, Kupfer S, Saunders EB. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701. PMID: 28493376; PMCID: PMC8031359.
      Citations: 4     Fields:    Translation:Humans
    261. Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese VM, Jamerson K, Gassman JJ, Smogorzewski M, Hsu CY. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801. PMID: 28473636; PMCID: PMC5576942.
      Citations: 14     Fields:    Translation:Humans
    262. Kario K, Bhatt DL, Brar S, Bakris GL. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circ J. 2017 Aug 25; 81(9):1337-1345. PMID: 28458378.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    263. Sternlicht H, Bakris GL. Resistant Hypertension: A Refractory Disease or Refractory Patient. Hypertension. 2017 04; 69(4):582-583. PMID: 28264919.
      Citations: 2     Fields:    Translation:Humans
    264. de Leeuw PW, Bisognano JD, Bakris GL, Nadim MK, Haller H, Kroon AA, DEBuT-HT and Rheos Trial Investigators. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843. PMID: 28320856.
      Citations: 35     Fields:    Translation:HumansCells
    265. Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921. PMID: 28246236.
      Citations: 23     Fields:    Translation:Humans
    266. Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Liu Y, Gourlie NM, Cannon CP, EXAMINE Investigators, Zannad F. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671. PMID: 28058763; PMCID: PMC5836868.
      Citations: 24     Fields:    Translation:HumansPHPublic Health
    267. Bakris G. Response by Bakris to Letter Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". Circulation. 2017 02 14; 135(7):e47. PMID: 28193804.
      Citations: 2     Fields:    
    268. Bakris G, Briasoulis A. Searching for the Optimal Blood Pressure Range in the Elderly: Are We There Yet? J Am Coll Cardiol. 2017 02 07; 69(5):494-496. PMID: 28153105.
      Citations:    Fields:    Translation:Humans
    269. Bakris G, Blacher J, Levy BI, Mourad JJ, Safar ME. Hypertension control and cardiovascular disease - Authors' reply. Lancet. 2017 01 14; 389(10065):154-155. PMID: 28102139.
      Citations: 1     Fields:    Translation:Humans
    270. Bakris G, Bhatt DL, Esler M, Fahy M, Kandzari D, Kario K, Mancia G, Weber M, Mahfoud F, Ewen S, Böhm M. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017 01 07; 38(2):93-100. PMID: 28158510; PMCID: PMC5381589.
      Citations: 57     Fields:    Translation:Humans
    271. Yano Y, Rakugi H, Bakris GL, Lloyd-Jones DM, Oparil S, Saruta T, Shimada K, Matsuoka H, Imai Y, Ogihara T. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227. PMID: 28049699.
      Citations: 8     Fields:    Translation:Humans
    272. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC. Diabetes Care: "Taking It to the Limit One More Time". Diabetes Care. 2017 01; 40(1):3-6. PMID: 27999000; PMCID: PMC5180460.
      Citations: 2     Fields:    
    273. Sternlicht H, Bakris GL. The Kidney in Hypertension. Med Clin North Am. 2017 Jan; 101(1):207-217. PMID: 27884230.
      Citations: 10     Fields:    Translation:Humans
    274. Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 01; 26(1):50-55. PMID: 27753685.
      Citations: 7     Fields:    Translation:Humans
    275. Halbach M, Bakris GL, Bisognano JD, Haller H, Beige J, Kroon AA, Nadim MK, Lovett EG, Schafer JE, de Leeuw PW, Wachter R. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017 02; 11(2):81-91. PMID: 28065708.
      Citations: 8     Fields:    Translation:Humans
    276. Skyler JS, Bakris GL, Darsow T, Eckel RH, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE, Bonifacio E, Groop L. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255. PMID: 27980006; PMCID: PMC5384660.
      Citations: 198     Fields:    Translation:Humans
    277. Bakris G, Vardeny O, Claggett B, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Solomon SD, Pitt B, Rossignol P, Girerd N, Fay R, Lamiral Z, Zannad F. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017 06; 19(6):792-799. PMID: 27868385.
      Citations: 13     Fields:    Translation:Humans
    278. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. PMID: 27753946.
      Citations:    
    279. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. PMID: 27754003.
      Citations:    
    280. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. PMID: 27754080.
      Citations:    
    281. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. PMID: 27754182.
      Citations:    
    282. Bakris GL, Burkart JM, Weinhandl ED, McCullough PA, Kraus MA. Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. Am J Kidney Dis. 2016 Nov; 68(5S1):S15-S23. PMID: 27772639.
      Citations: 5     Fields:    Translation:Humans
    283. McCullough PA, Chan CT, Weinhandl ED, Burkart JM, Bakris GL. Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. Am J Kidney Dis. 2016 Nov; 68(5S1):S5-S14. PMID: 27772643.
      Citations: 32     Fields:    Translation:Humans
    284. Kraus MA, Kansal S, Copland M, Komenda P, Weinhandl ED, Bakris GL, Chan CT, Fluck RJ, Burkart JM. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis. 2016 Nov; 68(5S1):S51-S58. PMID: 27772644.
      Citations: 6     Fields:    Translation:Humans
    285. Pocock SJ, Bakris G, Bhatt DL, Brar S, Fahy M, Gersh BJ. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. J Am Coll Cardiol. 2016 11 01; 68(18):2016-2025. PMID: 27788856.
      Citations: 17     Fields:    Translation:Humans
    286. Briasoulis A, Bakris GL. Current Status of Renal Denervation in Hypertension. Curr Cardiol Rep. 2016 11; 18(11):107. PMID: 27614466.
      Citations: 1     Fields:    Translation:Humans
    287. Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR, TECOS Study Group. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310. PMID: 27742728.
      Citations: 66     Fields:    Translation:Humans
    288. Dojki FK, Bakris G. Diabetes: Blood pressure goals in T2DM - time for a rethink? Nat Rev Endocrinol. 2016 11; 12(11):629-630. PMID: 27688044.
      Citations:    Fields:    Translation:Humans
    289. Al Dhaybi O, Bakris G. New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient. Am J Nephrol. 2016; 44(3):219-23. PMID: 27576478.
      Citations:    Fields:    Translation:Humans
    290. Bakris GL. The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure. Circulation. 2016 09 27; 134(13):904-5. PMID: 27576778.
      Citations: 18     Fields:    Translation:Humans
    291. Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT, Wyatt C, Hsu CY, Gutiérrez OM. BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol. 2017 02; 28(2):671-677. PMID: 27516235; PMCID: PMC5280023.
      Citations: 34     Fields:    Translation:Humans
    292. EXAMINE Investigators, White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13. PMID: 27480840.
      Citations: 8     Fields:    Translation:Humans
    293. Yamout H, Bakris GL. Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy. Nat Rev Nephrol. 2016 10; 12(10):583-4. PMID: 27425155.
      Citations:    Fields:    Translation:Humans
    294. Bakris GL, Molitch ME. Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss? Diabetes Care. 2016 Jul; 39(7):1287-91. PMID: 27330130.
      Citations: 14     Fields:    Translation:Humans
    295. Laffin LJ, Bakris GL. Renal Denervation: a Field in Flux. Curr Hypertens Rep. 2016 Jul; 18(7):56. PMID: 27245681.
      Citations: 1     Fields:    Translation:Humans
    296. Ruilope LM, Nowack C, Bakris GL. Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone. J Am Soc Hypertens. 2016 07; 10 Suppl 1:e7. PMID: 27677144.
      Citations: 3     Fields:    
    297. Weber MA, Bakris GL, White WB, Xie L, Bharucha D, Patel M. The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension. J Am Soc Hypertens. 2016 07; 10 Suppl 1:e8. PMID: 27677146.
      Citations:    Fields:    
    298. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704. PMID: 27350174.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    299. White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP, EXAMINE Investigators. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73. PMID: 27289121.
      Citations: 24     Fields:    Translation:Humans
    300. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Rich SS, D'Alessio D, Riddle MC, Reynolds L. Diabetes Care: "Lagniappe" and "Seeing Is Believing"! Diabetes Care. 2016 07; 39(7):1069-71. PMID: 27631957; PMCID: PMC5013720.
      Citations: 1     Fields:    
    301. Laffin LJ, Majewski C, Liao C, Bakris GL. Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study. J Clin Hypertens (Greenwich). 2016 12; 18(12):1216-1221. PMID: 27259699; PMCID: PMC8031884.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    302. Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, Oparil S, Robbins M, Townsend RR, Bakris G. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J. 2016 May 25; 80(6):1404-12. PMID: 27118620.
      Citations: 22     Fields:    Translation:Humans
    303. Stough WG, Epstein M, Alonso Garcia Mde L, Bakris GL, Butler J, Kosiborod M, Berman L, Rasmussen HS, Ruilope LM, Stockbridge N, Thompson A, Wittes J, Pitt B, Zannad F, Rossignol P, Mebazaa A. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. Int J Cardiol. 2016 Aug 01; 216:46-51. PMID: 27140336.
      Citations: 8     Fields:    Translation:Humans
    304. Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G, Zannad F, Alonso García Mde L, Hadjadj S, Koenig W, Scheen AJ. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016 07; 2(3):200-5. PMID: 27418973; PMCID: PMC4907355.
      Citations: 9     Fields:    Translation:HumansAnimals
    305. Bakris GL. Current and future potassium binders. Nephrol News Issues. 2016 Apr; 30(4):suppl 27-31. PMID: 27254903.
      Citations: 3     Fields:    Translation:Humans
    306. White WB, Lloyd E, Bakris GL, Kupfer S, Cuadra RH. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97. PMID: 26766564; PMCID: PMC4947533.
      Citations: 11     Fields:    Translation:Humans
    307. Majewski C, Bakris GL. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? Curr Diab Rep. 2016 Apr; 16(4):24. PMID: 26879307.
      Citations: 7     Fields:    Translation:Humans
    308. Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307. PMID: 27060568; PMCID: PMC8032014.
      Citations: 11     Fields:    Translation:Humans
    309. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004. PMID: 26954408.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    310. Bakris G, Blacher J, Levy BI, Mourad JJ, Safar ME. From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. Lancet. 2016 Jul 30; 388(10043):530-2. PMID: 26856636.
      Citations: 24     Fields:    Translation:Humans
    311. Sternlicht H, Bakris GL. Hydrochlorothiazide as the Diuretic of Choice for Hypertension: Time to Kick the Habit. J Am Coll Cardiol. 2016 Feb 02; 67(4):390-391. PMID: 26821626.
      Citations: 2     Fields:    Translation:Humans
    312. Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, Cushman WC, Mehta CR, Bakris GL, White WB, EXAMINE Investigators, Zannad F. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27. PMID: 27179720.
      Citations: 3     Fields:    Translation:Humans
    313. Bakris GL, Nowack C. Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply. JAMA. 2016 Jan 19; 315(3):306. PMID: 26784785.
      Citations: 1     Fields:    Translation:Humans
    314. Sternlicht H, Bakris GL. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Blood Purif. 2016; 41(1-3):139-43. PMID: 26766168.
      Citations: 5     Fields:    Translation:Humans
    315. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Hill Golden S, Rich SS, D'Alessio D, Reynolds L. Building Momentum: Taking on the Real “Issues” of Diabetes Care! Diabetes Care. 2016 Jan; 39(1):10-12. PMID: 27606379; PMCID: PMC4822403.
      Citations: 1     Fields:    Translation:Humans
    316. Sternlicht H, Bakris GL. Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. Nat Rev Nephrol. 2016 Mar; 12(3):128-9. PMID: 26714579.
      Citations:    Fields:    Translation:Humans
    317. Yeh JS, Bakris GL, Taler SJ. CLINICAL DECISIONS. Blood-Pressure Control. N Engl J Med. 2015 Nov 26; 373(22):2180-2. PMID: 26551540.
      Citations: 1     Fields:    Translation:Humans
    318. Puri R, Nissen SE, Menon V, Shao M, Hsu A, Bakris GL, Kastelein JJ, Williams B, Armbrecht J, Brunel P, Kataoka Y, Nicholls SJ. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9. PMID: 26523993.
      Citations: 2     Fields:    Translation:Humans
    319. Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Vanholder R, Wiecek A, Zoccali C, ERA-EDTA EURECA-m working group, Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network, Rossignol P, Massy ZA, Azizi M, Ortiz A, London GM, Stengel B, Fouque D, Red de Investigación Renal (REDINREN) network. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015 Oct 17; 386(10003):1588-98. PMID: 26530623.
      Citations: 54     Fields:    Translation:Humans
    320. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct; 17(10):1057-65. PMID: 26459796; PMCID: PMC5057342.
      Citations: 55     Fields:    Translation:Humans
    321. Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7. PMID: 26558819.
      Citations: 14     Fields:    Translation:Humans
    322. Sternlicht H, Bakris GL. Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034. PMID: 26414969.
      Citations: 5     Fields:    Translation:Humans
    323. Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015 Dec; 88(6):1427-1433. PMID: 26376130; PMCID: PMC4678168.
      Citations: 37     Fields:    
    324. Sarafidis PA, Georgianos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother. 2015; 16(14):2205-15. PMID: 26330193.
      Citations: 15     Fields:    Translation:Humans
    325. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Kimmeskamp-Kirschbaum N, Ruilope LM, Remuzzi G, Pieper A, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94. PMID: 26325557.
      Citations: 196     Fields:    Translation:HumansCTClinical Trials
    326. Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension. 2015 Oct; 66(4):731-8. PMID: 26303290.
      Citations: 23     Fields:    Translation:Humans
    327. Giles TD, Bakris G, Oparil S, Weber MA, Li H, Mallick M, Bharucha DB, Chen C, Ferguson WG, NAC-MD-01 Substudy Investigators. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015 Nov; 9(11):845-54. PMID: 26362831.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    328. Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G, SYMPLICITY HTN-3 Investigators. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779. PMID: 26362830.
      Citations: 18     Fields:    Translation:Humans
    329. Patney V, Whaley-Connell A, Bakris G. Hypertension Management in Diabetic Kidney Disease. Diabetes Spectr. 2015 Aug; 28(3):175-80. PMID: 26300610; PMCID: PMC4536650.
      Citations: 15     
    330. Iliescu R, Lohmeier TE, Tudorancea I, Laffin L, Bakris GL. Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol. 2015 Oct 01; 309(7):F583-94. PMID: 26224718; PMCID: PMC4593817.
      Citations: 21     Fields:    Translation:Humans
    331. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61. PMID: 26172895.
      Citations: 141     Fields:    Translation:HumansCTClinical Trials
    332. Bakris G. Summary and Conclusions. High Blood Press Cardiovasc Prev. 2015 Jul; 22 Suppl 1:S23. PMID: 26149526.
      Citations:    Fields:    Translation:Humans
    333. Cefalu WT, Boulton AJ, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Golden SH, Rich S, Reynolds L. Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future! Diabetes Care. 2015 Jul; 38(7):1177-80. PMID: 26312261; PMCID: PMC5131862.
      Citations: 4     Fields:    
    334. de Leeuw PW, Bakris GL, Nadim MK, Haller H, Lovett EG, Bisognano JD. 8B.06: BAROREFLEX ACTIVATION THERAPY CONSISTENTLY MAINTAINS BLOOD PRESSURE REDUCTION IN A LARGE RESISTANT HYPERTENSION COHORT FOR AT LEAST 6 YEARS. J Hypertens. 2015 Jun; 33 Suppl 1:e108. PMID: 26102672.
      Citations:    
    335. Kario K, Bakris GL, Bhatt D. 4A.10: PREFERENTIAL REDUCTION IN MORNING/NOCTURNAL HYPERTENSION BY RENAL DENERVATION FOR DRUG- RESISTANT HYPERTENSION: A NEW ABPM ANALYSIS OF SYMPLICITY HTN-3 AND HTN-JAPAN. J Hypertens. 2015 Jun; 33 Suppl 1:e52. PMID: 26102846.
      Citations:    
    336. Laffin LJ, Bakris GL. Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37. PMID: 25899655.
      Citations: 1     Fields:    Translation:Humans
    337. Weir MR, Bakris GL, Pitt B. New agents for hyperkalemia. N Engl J Med. 2015 04 16; 372(16):1570-1. PMID: 25875263.
      Citations:    Fields:    Translation:Humans
    338. Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321. PMID: 25835443.
      Citations: 50     Fields:    Translation:Humans
    339. Glassock RJ, Bakris GL. Hypertension: Impact of blood pressure lowering in type 2 diabetes. Nat Rev Nephrol. 2015 Jun; 11(6):320-1. PMID: 25848880.
      Citations:    Fields:    Translation:Humans
    340. Briasoulis A, Bakris GL. A clinician's perspective of the role of renal sympathetic nerves in hypertension. Front Physiol. 2015; 6:75. PMID: 25859218; PMCID: PMC4373248.
      Citations: 3     
    341. Bakris GL, Bhatt DL. Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3. J Am Coll Cardiol. 2015 Mar 10; 65(9):959-60. PMID: 25744018.
      Citations: 1     Fields:    Translation:Humans
    342. Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators, Zannad F. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76. PMID: 25765696.
      Citations: 242     Fields:    Translation:Humans
    343. Laffin LJ, Bakris GL. Endothelin antagonism and hypertension: an evolving target. Semin Nephrol. 2015 Mar; 35(2):168-75. PMID: 25966348.
      Citations: 9     Fields:    Translation:Humans
    344. Laffin LJ, Bakris GL. Renal denervation for resistant hypertension and beyond. Adv Chronic Kidney Dis. 2015 Mar; 22(2):133-9. PMID: 25704350.
      Citations: 2     Fields:    Translation:Humans
    345. Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30. PMID: 25715414; PMCID: PMC4876696.
      Citations: 41     Fields:    Translation:Humans
    346. McMullan CJ, Yano Y, Bakris GL, Kario K, Phillips RA, Forman JP. Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. J Am Soc Hypertens. 2015 Apr; 9(4):299-306. PMID: 25891362.
      Citations: 6     Fields:    Translation:Humans
    347. Elliott WJ, Whitmore J, Feldstein JD, Bakris GL. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015 Apr; 9(4):266-74. PMID: 25804495.
      Citations: 2     Fields:    Translation:Humans
    348. Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81. PMID: 25591469.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    349. Laffin LJ, Bakris GL. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015 Apr; 21:20-4. PMID: 25541034.
      Citations: 3     Fields:    Translation:HumansAnimals
    350. Schumacher H, Schmieder RE, Mann JF, Teo K, Lonn E, Sleight P, Mancia G, Sliwa K, Bakris G, Yusuf S, Böhm M, Linz D, Mahfoud F, Ukena C. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49. PMID: 25431275.
      Citations: 14     Fields:    Translation:Humans
    351. Sarafidis PA, Bakris GL. Cardiovascular disease in CKD in 2014: new insights into cardiovascular risk factors and outcomes. Nat Rev Nephrol. 2015 Feb; 11(2):70-2. PMID: 25511758.
      Citations: 6     Fields:    Translation:Humans
    352. Briasoulis A, Bakris G. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8. PMID: 25828371.
      Citations: 8     Fields:    Translation:Humans
    353. Nathan S, Bakris GL. The future of renal denervation in resistant hypertension. Curr Hypertens Rep. 2014 Dec; 16(12):494. PMID: 25304105.
      Citations: 3     Fields:    Translation:HumansAnimals
    354. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21. PMID: 25415805.
      Citations: 218     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    355. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27. PMID: 25400162; PMCID: PMC4301597.
      Citations: 174     Fields:    Translation:Humans
    356. Zannad F, Stough WG, Mahfoud F, Bakris GL, Kjeldsen SE, Kieval RS, Haller H, Yared N, De Ferrari GM, Piña IL, Stein K, Azizi M. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. Hypertension. 2015 Jan; 65(1):5-15. PMID: 25350982.
      Citations: 4     Fields:    Translation:HumansCells
    357. Chin MP, Wrolstad D, Bakris GL, Chertow GM, de Zeeuw D, Goldsberry A, Linde PG, McCullough PA, McMurray JJ, Wittes J, Meyer CJ. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec; 20(12):953-8. PMID: 25307295.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    358. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33. PMID: 25257325.
      Citations: 227     Fields:    Translation:Humans
    359. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83. PMID: 25249672; PMCID: PMC4170131.
      Citations: 372     Fields:    Translation:Humans
    360. Yamout H, Bakris GL. In search for the 'sweet spot' for blood pressure level in diabetes. Heart. 2014 Sep 15; 100(18):1404-5. PMID: 25073888.
      Citations:    Fields:    Translation:Humans
    361. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G, DIA3004 Study Group. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27. PMID: 24965700.
      Citations: 98     Fields:    Translation:Humans
    362. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, Vijapurkar U, Kline I, Usiskin K, Meininger G, Bakris G. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74. PMID: 25059406.
      Citations: 41     Fields:    Translation:Humans
    363. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57. PMID: 25418497.
      Citations: 21     Fields:    Translation:Humans
    364. Bhatt DL, Bakris GL. Renal denervation for resistant hypertension. N Engl J Med. 2014 07 10; 371(2):184. PMID: 25006731.
      Citations: 14     Fields:    Translation:Humans
    365. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry RR, Hill Golden S, Rich S, Reynolds L. Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care. 2014 Jul; 37(7):1782-5. PMID: 25093231; PMCID: PMC5131856.
      Citations: 4     Fields:    Translation:Humans
    366. Chin MP, Reisman SA, Bakris GL, O'Grady M, Linde PG, McCullough PA, Packham D, Vaziri ND, Ward KW, Warnock DG, Meyer CJ. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014; 39(6):499-508. PMID: 24903467.
      Citations: 73     Fields:    Translation:HumansAnimalsCTClinical Trials
    367. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014 Sep 16; 64(11):1071-8. PMID: 24858423.
      Citations: 60     Fields:    Translation:Humans
    368. Yamout H, Lazich I, Bakris GL. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014 May; 21(3):281-6. PMID: 24780456.
      Citations: 24     Fields:    Translation:Humans
    369. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014 May; 34(3):333-9. PMID: 25016403.
      Citations: 36     Fields:    Translation:Humans
    370. Bakris GL. The role of aldosterone in the spectrum of cardiovascular and kidney disease risk: introduction. Semin Nephrol. 2014 May; 34(3):245-6. PMID: 25016396.
      Citations:    Fields:    Translation:Humans
    371. Weber MA, White WB, Sica D, Bakris GL, Cao C, Roberts A, Kupfer S. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7. PMID: 24445723; PMCID: PMC3966914.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    372. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10; 370(15):1393-401. PMID: 24678939.
      Citations: 637     Fields:    Translation:Humans
    373. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35. PMID: 24637941; PMCID: PMC4165641.
      Citations: 6     Fields:    Translation:Humans
    374. Byrd JB, Bakris G, Jamerson K. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. Curr Hypertens Rep. 2014 Mar; 16(3):419. PMID: 24474031.
      Citations: 1     Fields:    Translation:Humans
    375. Sarafidis PA, Bakris GL. Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014 Mar; 15(1):97-8. PMID: 24526392.
      Citations:    Fields:    Translation:Humans
    376. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-Dehoff RM. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43. PMID: 24299915; PMCID: PMC4118668.
      Citations: 45     Fields:    Translation:Humans
    377. Vemulapalli S, Ard J, Bakris GL, Bhatt DL, Brown AS, Cushman WC, Ferdinand KC, Flack JM, Fleg JL, Katzen BT, Kostis JB, Oparil S, Patel CB, Pepine CJ, Rocha-Singh KJ, Townsend RR, Peterson ED, Califf RM, Patel MR, Piña IL. Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014 Jun; 167(6):775-88.e1. PMID: 24890525.
      Citations: 9     Fields:    Translation:HumansCells
    378. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May; 8(5):330-9. PMID: 24631482.
      Citations: 79     Fields:    Translation:Humans
    379. Sarafidis PA, Bakris GL. Early patterns of blood pressure change and future coronary atherosclerosis. JAMA. 2014 Feb 05; 311(5):471-2. PMID: 24496535.
      Citations: 4     Fields:    Translation:Humans
    380. Briasoulis A, Silver A, Yano Y, Bakris GL. Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. J Clin Hypertens (Greenwich). 2014 Feb; 16(2):141-8. PMID: 24588814; PMCID: PMC8031868.
      Citations: 8     Fields:    Translation:HumansCells
    381. Yano Y, Bakris GL, Inokuchi T, Ohba Y, Tamaki N, Nagata M, Kuwabara M, Yokota N, Eto T, Kuroki M, Shimada K, Kario K. Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients. J Hypertens. 2014 Feb; 32(2):423-31. PMID: 24351802.
      Citations: 11     Fields:    Translation:Humans
    382. Tsioufis C, Kasiakogias A, Kordalis A, Dimitriadis K, Thomopoulos C, Tsiachris D, Vasileiou P, Doumas M, Makris T, Papademetriou V, Kallikazaros I, Bakris G, Stefanadis C. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22. PMID: 24241057.
      Citations: 33     Fields:    Translation:Humans
    383. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan; 32(1):3-15. PMID: 24270181.
      Citations: 218     Fields:    Translation:Humans
    384. Briasoulis A, Bakris G. The future of interventional management of hypertension: threats and opportunities. Curr Vasc Pharmacol. 2014 Jan; 12(1):69-76. PMID: 23905592.
      Citations: 3     Fields:    Translation:HumansCells
    385. Oliva RV, Bakris GL. Sympathetic activation in resistant hypertension: theory and therapy. Semin Nephrol. 2014; 34(5):550-9. PMID: 25416664.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    386. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75. PMID: 24558077.
      Citations: 58     Fields:    Translation:Humans
    387. Thomas CC, Bakris G. Metformin nephrotoxicity insights: will they change clinical management? J Diabetes. 2014 Mar; 6(2):111-2. PMID: 24274706.
      Citations: 2     Fields:    Translation:HumansAnimals
    388. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):14-26. PMID: 24341872; PMCID: PMC8031779.
      Citations: 354     Fields:    Translation:Humans
    389. Yamout H, Bakris GL. Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus. Hypertension. 2014 Feb; 63(2):220-1. PMID: 24324049.
      Citations:    Fields:    Translation:Humans
    390. Bakris G, Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014 May 13; 63(18):1924-5. PMID: 24315916.
      Citations: 6     Fields:    Translation:Humans
    391. Bakris G, Sarafidis P, Agarwal R, Ruilope L. Review of blood pressure control rates and outcomes. J Am Soc Hypertens. 2014 Feb; 8(2):127-41. PMID: 24309125.
      Citations: 29     Fields:    Translation:Humans
    392. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8. PMID: 24297687.
      Citations: 80     Fields:    Translation:Humans
    393. Bakris GL, Doghramji PP, Keenan RT, Silber SH. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Am J Med. 2014 Jan; 127(1):S1. PMID: 24268074.
      Citations: 1     Fields:    Translation:Humans
    394. Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM, BEACON Trial Investigators, de Zeeuw D. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 12 26; 369(26):2492-503. PMID: 24206459; PMCID: PMC4496027.
      Citations: 419     Fields:    Translation:HumansCTClinical Trials
    395. Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50. PMID: 24169612.
      Citations: 10     Fields:    Translation:Humans
    396. Yano Y, Briasoulis A, Bakris GL, Hoshide S, Wang JG, Shimada K, Kario K. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens. 2014 Feb; 8(2):103-16. PMID: 24157055.
      Citations: 13     Fields:    Translation:Humans
    397. Bakris G. Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better. Nat Rev Nephrol. 2013 Nov; 9(11):634-5. PMID: 24080799.
      Citations: 2     Fields:    Translation:Humans
    398. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Campese VM, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD, Böhm M. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013 Dec 03; 62(22):2031-45. PMID: 24021387.
      Citations: 33     Fields:    Translation:Humans
    399. Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1135-44. PMID: 23999933.
      Citations: 28     Fields:    Translation:Humans
    400. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35. PMID: 23992602.
      Citations: 846     Fields:    Translation:Humans
    401. Yano Y, Bakris GL, Matsushita K, Hoshide S, Shimada K, Kario K. Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly. Am J Nephrol. 2013; 38(3):195-203. PMID: 23970169.
      Citations: 3     Fields:    Translation:Humans
    402. Bakris G, Fafin C, Favre G, Pradier C, Esnault VL, Moranne O. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013 Oct; 8(10):1694-701. PMID: 23929924; PMCID: PMC3789346.
      Citations: 14     Fields:    Translation:Humans
    403. Briasoulis A, Bakris G. Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience. J Hypertens. 2013 Aug; 31(8):1537-8. PMID: 23822927.
      Citations: 3     Fields:    Translation:Humans
    404. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70. PMID: 23900000; PMCID: PMC3755935.
      Citations: 5     Fields:    Translation:HumansCells
    405. Rajagopalan S, Bakris GL, Abraham WT, Pitt B, Brook RD. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013 Sep; 62(3):444-9. PMID: 23876474.
      Citations: 4     Fields:    Translation:HumansAnimals
    406. Bakris GL. The author replies. Kidney Int. 2013 Jul; 84(1):215. PMID: 23812368.
      Citations:    Fields:    Translation:Humans
    407. Weber MA, Bakris GL, Weir MR, Jamerson K. Obesity, blood pressure, and cardiovascular outcomes - Authors' reply. Lancet. 2013 Jun 08; 381(9882):1982-3. PMID: 23746892.
      Citations:    Fields:    Translation:Humans
    408. Bakris GL. Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6. PMID: 23736520.
      Citations: 2     Fields:    Translation:Humans
    409. Flynn C, Bakris GL. Role of ambulatory blood pressure monitoring in hypertension and diabetes. Curr Hypertens Rep. 2013 Jun; 15(3):137-42. PMID: 23595358.
      Citations: 3     Fields:    Translation:Humans
    410. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013 Aug; 62(2):201-13. PMID: 23684145; PMCID: PMC3929429.
      Citations: 78     Fields:    Translation:Humans
    411. Bakris GL. Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted? J Diabetes Complications. 2013 Sep-Oct; 27(5):415-6. PMID: 23659775.
      Citations:    Fields:    Translation:Humans
    412. Briasoulis A, Bakris G. Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention. 2013 May; 9 Suppl R:R136-9. PMID: 23732146.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    413. Briasoulis A, Oliva R, Kalaitzidis R, Flynn C, Lazich I, Schlaffer C, Bakris G. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9. PMID: 23815535; PMCID: PMC8033810.
      Citations: 8     Fields:    Translation:Humans
    414. Elliott WJ, Egan B, Giles TD, Bakris GL, White WB, Sansone TM. Rationale for establishing a mechanism to increase reimbursement to hypertension specialists. J Clin Hypertens (Greenwich). 2013 Jun; 15(6):397-403. PMID: 23730988; PMCID: PMC8033840.
      Citations: 5     Fields:    Translation:Humans
    415. Bakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, Hester A, Hua T, Zappe D, Pitt B, ACCOMPLISH Investigators. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013 Jul 15; 112(2):255-9. PMID: 23582626.
      Citations: 7     Fields:    Translation:Humans
    416. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8. PMID: 23541376.
      Citations: 26     Fields:    Translation:Humans
    417. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73. PMID: 23464594; PMCID: PMC3654568.
      Citations: 182     Fields:    Translation:HumansCTClinical Trials
    418. Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S, Bönner G. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013 Aug; 27(8):479-86. PMID: 23514842; PMCID: PMC3715765.
      Citations: 13     Fields:    Translation:Humans
    419. Yano Y, Bakris GL. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens. 2013 May-Jun; 7(3):244-52. PMID: 23523411.
      Citations: 12     Fields:    Translation:Humans
    420. McMullan CJ, Bakris GL, Phillips RA, Forman JP. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8. PMID: 23493382; PMCID: PMC3641624.
      Citations: 27     Fields:    Translation:Humans
    421. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013 Mar; 15(3):340. PMID: 23338722.
      Citations: 58     Fields:    Translation:Humans
    422. de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol. 2013; 37(3):212-22. PMID: 23467003.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    423. Bakris G. Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective. Nat Rev Endocrinol. 2013 Mar; 9(3):138-9. PMID: 23381031.
      Citations:    Fields:    Translation:Humans
    424. Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013 Mar; 9(3):147-53. PMID: 23358424.
      Citations: 11     Fields:    Translation:Humans
    425. Briasoulis A, Bakris GL. The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int. 2013 Jan; 83(1):20-2. PMID: 23271487.
      Citations:    Fields:    Translation:Humans
    426. Socolovsky C, Masi C, Hamlish T, Aduana G, Arora S, Bakris G, Johnson D. Evaluating the role of key learning theories in ECHO: a telehealth educational program for primary care providers. Prog Community Health Partnersh. 2013; 7(4):361-8. PMID: 24375176.
      Citations: 25     Fields:    Translation:Humans
    427. Babayev R, Whaley-Connell A, Kshirsagar A, Klemmer P, Navaneethan S, Chen SC, Li S, McCullough PA, Bakris G, Bomback A, KEEP Investigators. Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013 Mar; 61(3):404-12. PMID: 23260275.
      Citations: 21     Fields:    Translation:Humans
    428. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16; 381(9866):537-45. PMID: 23219284.
      Citations: 36     Fields:    Translation:Humans
    429. Cunnane RT, Bakris GL. Hypertensive goals in patients with coronary artery disease. Curr Cardiol Rep. 2012 Dec; 14(6):667-72. PMID: 22890754.
      Citations:    Fields:    Translation:Humans
    430. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension--its identification and epidemiology. Nat Rev Nephrol. 2013 Jan; 9(1):51-8. PMID: 23165303.
      Citations: 65     Fields:    Translation:Humans
    431. Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbai F, Hiremath L, Jamerson K, Kendrick C, Kusek JW, Lash JP, Lea J, Miller ER, Rostand S, Toto R, Wang X, Wright JT, Appel LJ. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8. PMID: 23172931; PMCID: PMC3523681.
      Citations: 32     Fields:    Translation:Humans
    432. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL, REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14. PMID: 23144048.
      Citations: 79     Fields:    Translation:Humans
    433. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Fiuzat M, O'Connor CM, Zannad F, Pitt B, Piña IL. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 01; 167(5):1677-87. PMID: 23121914; PMCID: PMC4145865.
      Citations: 42     Fields:    Translation:HumansAnimals
    434. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100. PMID: 23339726; PMCID: PMC8108251.
      Citations: 12     Fields:    Translation:Humans
    435. Briasoulis A, Bakris GL. Timing and efficacy of alternative methods of sympathetic blockade. Curr Hypertens Rep. 2012 Oct; 14(5):455-61. PMID: 22833367.
      Citations: 1     Fields:    Translation:HumansCells
    436. Sarafidis PA, Bakris GL. Use of a single target blood pressure level in type 2 diabetes mellitus for all cardiovascular risk reduction: comment on "intensive and standard blood pressure targets in patients with type 2 diabetes mellitus". Arch Intern Med. 2012 Sep 24; 172(17):1304-5. PMID: 22868907.
      Citations: 2     Fields:    
    437. Guralnick A, Bakris GL. Approaches for targeting blood pressure control in sleep disorders. Curr Opin Nephrol Hypertens. 2012 Sep; 21(5):469-74. PMID: 22820373.
      Citations: 2     Fields:    Translation:Humans
    438. Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Sabbah HN, Sica DA, Tavazzi L, Pitt B, Zannad F, Piña IL. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov; 33(22):2782-95. PMID: 22942339.
      Citations: 48     Fields:    Translation:HumansAnimals
    439. Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, Song E, Kupfer S. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 Dec; 125(12):1229.e1-1229.e10. PMID: 22939358.
      Citations: 31     Fields:    Translation:Humans
    440. Oliva RV, Bakris GL. Management of hypertension in the elderly population. J Gerontol A Biol Sci Med Sci. 2012 Dec; 67(12):1343-51. PMID: 22913963.
      Citations: 10     Fields:    Translation:Humans
    441. Bhatt DL, Bakris GL. The promise of renal denervation. Cleve Clin J Med. 2012 Jul; 79(7):498-500. PMID: 22751634.
      Citations: 3     Fields:    Translation:Humans
    442. Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012 Sep 01; 380(9844):783-5. PMID: 22717316.
      Citations: 4     Fields:    Translation:Humans
    443. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug; 60(2):310-8. PMID: 22710649.
      Citations: 23     Fields:    Translation:Humans
    444. Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012; 178:100-105. PMID: 22652724.
      Citations: 9     Fields:    Translation:Humans
    445. Whaley-Connell A, Shlipak MG, Inker LA, Kurella Tamura M, Bomback AS, Saab G, Szpunar SM, McFarlane SI, Li S, Chen SC, Norris K, Bakris GL, McCullough PA, Kidney Early Evaluation Program Investigators. Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med. 2012 Jul; 125(7):661-9. PMID: 22626510; PMCID: PMC3383388.
      Citations: 28     Fields:    Translation:HumansPHPublic Health
    446. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35. PMID: 22573363; PMCID: PMC6652693.
      Citations: 89     Fields:    Translation:Humans
    447. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012 May; 30(5):874-6. PMID: 22495128.
      Citations: 18     Fields:    Translation:Humans
    448. Gulati M, Black HR, Arnsdorf MF, Shaw LJ, Bakris GL. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt). 2012 Sep; 21(9):917-24. PMID: 22480201.
      Citations: 4     Fields:    Translation:Humans
    449. Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012 May; 14(5):284-92. PMID: 22533654; PMCID: PMC8108928.
      Citations: 23     Fields:    Translation:Humans
    450. Sharma AM, Bakris G, Neutel JM, Littlejohn TW, Kobe M, Ting N, Ley L. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51. PMID: 22386829.
      Citations: 9     Fields:    Translation:Humans
    451. Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012 Mar; 10(2):156-61. PMID: 22239626.
      Citations: 7     Fields:    Translation:Humans
    452. Oliva RV, Bakris GL. Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease? J Hypertens. 2012 Mar; 30(3):466-7. PMID: 22317991.
      Citations:    Fields:    Translation:Humans
    453. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr; 6(2):152-8. PMID: 22341199.
      Citations: 78     Fields:    Translation:Humans
    454. Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, Feller MA, Love TE, Aban IB, Levesque R, Ekundayo OJ, Dell'Italia LJ, Bakris GL, Rich MW. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012 Apr; 125(4):399-410. PMID: 22321760; PMCID: PMC3324926.
      Citations: 34     Fields:    Translation:Humans
    455. Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012 Feb; 163(2):156-63. PMID: 22305831.
      Citations: 35     Fields:    Translation:HumansCells
    456. Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, Bakris G, McCullough PA, Shlipak M, KEEP Investigators. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7. PMID: 22232147; PMCID: PMC3417125.
      Citations: 49     Fields:    Translation:Humans
    457. Sarafidis PA, Bakris G. A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique? J Hypertens. 2012 Jan; 30(1):48-50. PMID: 22157588.
      Citations:    Fields:    Translation:Humans
    458. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76. PMID: 22189843.
      Citations: 13     Fields:    Translation:HumansCells
    459. Bakris GL. Hypertension in 2011: New insights--from risk factors to treatment implications. Nat Rev Cardiol. 2011 Dec 13; 9(2):75-7. PMID: 22158080.
      Citations: 4     Fields:    Translation:Humans
    460. Masi C, Hamlish T, Davis A, Bordenave K, Brown S, Perea B, Aduana G, Wolfe M, Bakris G, Johnson D. Using an established telehealth model to train urban primary care providers on hypertension management. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):45-50. PMID: 22235823; PMCID: PMC8108817.
      Citations: 10     Fields:    Translation:Humans
    461. Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep. 2011 Dec; 13(6):452-5. PMID: 21904985.
      Citations: 3     Fields:    Translation:Humans
    462. Lazich I, Sarafidis P, de Guzman E, Patel A, Oliva R, Bakris G. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6. PMID: 21955403.
      Citations: 6     Fields:    Translation:Humans
    463. Guichard JL, Desai RV, Ahmed MI, Mujib M, Fonarow GC, Feller MA, Ekundayo OJ, Bittner V, Aban IB, White M, Aronow WS, Love TE, Bakris GL, Zieman SJ, Ahmed A. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011 Nov; 58(5):895-901. PMID: 21947466; PMCID: PMC3390027.
      Citations: 22     Fields:    Translation:Humans
    464. Bhavsar NA, Appel LJ, Kusek JW, Contreras G, Bakris G, Coresh J, Astor BC, AASK Study Group. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis. 2011 Dec; 58(6):886-93. PMID: 21944667; PMCID: PMC3221777.
      Citations: 41     Fields:    Translation:Humans
    465. Mensah GA, Bakris G. The United Nations high level meeting addresses noncommunicable diseases, but where is hypertension? J Clin Hypertens (Greenwich). 2011 Nov; 13(11):787-90. PMID: 22051421; PMCID: PMC8108954.
      Citations: 2     Fields:    Translation:Humans
    466. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1. PMID: 21982652.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    467. Lazich I, Bakris GL. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage? Curr Opin Nephrol Hypertens. 2011 Sep; 20(5):471-5. PMID: 21709549.
      Citations:    Fields:    Translation:Humans
    468. Lazich I, Bakris GL. Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. Contrib Nephrol. 2011; 172:223-234. PMID: 21894002.
      Citations: 4     Fields:    Translation:Humans
    469. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Velazquez EJ, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M, Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hyperten, Dahlöf B. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Press. 2012 Apr; 21(2):82-7. PMID: 21830844.
      Citations: 2     Fields:    Translation:Humans
    470. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 09; 58(7):765-73. PMID: 21816315.
      Citations: 173     Fields:    Translation:HumansCTClinical Trials
    471. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Stein JH, Weitz HH. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352. PMID: 21771565.
      Citations: 50     Fields:    Translation:Humans
    472. Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72. PMID: 21762358; PMCID: PMC8108745.
      Citations: 42     Fields:    Translation:Humans
    473. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM, National Academy of Clinical Biochemistry, Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):e61-99. PMID: 21617108; PMCID: PMC3114322.
      Citations: 143     Fields:    Translation:Humans
    474. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM, National Academy of Clinical Biochemistry. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):1419-23. PMID: 21617111; PMCID: PMC3114347.
      Citations: 51     Fields:    Translation:Humans
    475. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):e1-e47. PMID: 21617152.
      Citations: 125     Fields:    Translation:Humans
    476. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):793-8. PMID: 21617153.
      Citations: 30     Fields:    Translation:Humans
    477. Bakris GL. American Society of Hypertension, Inc: Leadership message. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):533. PMID: 21762368; PMCID: PMC8816463.
      Citations:    Fields:    Translation:Humans
    478. Brown WV, Bakris G, Lerma E, Chertow G. Assessment and management of vascular disease risk in patients with chronic kidney disease. J Clin Lipidol. 2011 Jul-Aug; 5(4):251-60. PMID: 21784369.
      Citations:    Fields:    Translation:Humans
    479. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 May; 86(5):444-56. PMID: 21531886; PMCID: PMC3084647.
      Citations: 58     Fields:    Translation:Humans
    480. Bakris G, Weir MR, Schmieder RE. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73. PMID: 21374585.
      Citations: 4     Fields:    Translation:Humans
    481. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011 May 17; 57(20):2037-114. PMID: 21524875.
      Citations: 161     Fields:    Translation:Humans
    482. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31; 123(21):2434-506. PMID: 21518977.
      Citations: 118     Fields:    Translation:Humans
    483. Saab G, Whaley-Connell A, Bombeck A, Kurella Tamura M, Li S, Chen SC, McFarlane SI, Sowers JR, Norris K, Bakris GL, McCullough PA, Kidney Early Evaluation Program Investigators. The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. Cardiorenal Med. 2011; 1(2):123-130. PMID: 22258399; PMCID: PMC3101512.
      Citations: 7     Fields:    
    484. Flynn C, Bakris GL. Interaction between Adiponectin and Aldosterone. Cardiorenal Med. 2011; 1(2):96-101. PMID: 22258396; PMCID: PMC3101509.
      Citations: 12     Fields:    
    485. Bakris GL. CON: blood pressure treatment goal for patients with diabetes should be <130/80 mm Hg. J Clin Hypertens (Greenwich). 2011 Apr; 13(4):263-5. PMID: 21466622; PMCID: PMC8672985.
      Citations: 3     Fields:    Translation:Humans
    486. Bakris GL. Blood pressure targets in diabetes: is this the time for change?--CON (Rebuttal). J Clin Hypertens (Greenwich). 2011 Apr; 13(4):268-9. PMID: 21466624; PMCID: PMC8673118.
      Citations: 1     Fields:    Translation:Humans
    487. Ruilope LM, Bakris GL. Renal function and target organ damage in hypertension. Eur Heart J. 2011 Jul; 32(13):1599-604. PMID: 21444366.
      Citations: 29     Fields:    Translation:Humans
    488. White WB, Schnitzer TJ, Bakris GL, Frayssinet H, Duquesroix B, Weber M. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol. 2011 May 01; 107(9):1338-45. PMID: 21371681.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    489. McFarlane SI, McCullough PA, Sowers JR, Soe K, Chen SC, Li S, Vassalotti JA, Stevens LA, Salifu MO, Kurella Tamura M, Bomback AS, Norris KC, Collins AJ, Bakris GL, Whaley-Connell AT, KEEP Steering Committee. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31. PMID: 21338847; PMCID: PMC3237700.
      Citations: 8     Fields:    Translation:Humans
    490. McCullough PA, Brown WW, Gannon MR, Vassalotti JA, Collins AJ, Chen SC, Bakris GL, Whaley-Connell AT. Sustainable community-based CKD screening methods employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S4-8. PMID: 21338848.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    491. Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-Connell AT, Bakris GL, McCullough PA. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16. PMID: 21338849; PMCID: PMC3298760.
      Citations: 54     Fields:    Translation:HumansPHPublic Health
    492. McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL, Whaley-Connell AT. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary. Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S1-3. PMID: 21338845.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    493. Udani SM, Bakris GL. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1. PMID: 21301489.
      Citations: 2     Fields:    Translation:Humans
    494. Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8. PMID: 21272195; PMCID: PMC8673073.
      Citations: 56     Fields:    Translation:Humans
    495. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20. PMID: 21282560.
      Citations: 78     Fields:    Translation:Humans
    496. Whaley-Connell A, Bomback AS, McFarlane SI, Li S, Roberts T, Chen SC, Collins AJ, Norris K, Bakris GL, Sowers JR, McCullough PA, Kidney Early Evaluation Program Investigators. Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. Cardiorenal Med. 2011; 1(1):45-52. PMID: 22258465; PMCID: PMC3101520.
      Citations: 11     Fields:    
    497. Lazich I, Bakris G. Initial combination antihypertensives: let's ACCELERATE. Lancet. 2011 Jan 22; 377(9762):278-9. PMID: 21236482.
      Citations:    Fields:    Translation:Humans
    498. Jamerson KA, Devereux R, Bakris GL, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA, Dahlöf B. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9. PMID: 21189401.
      Citations: 13     Fields:    Translation:Humans
    499. Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011 Mar; 13(3):146-54. PMID: 21366845; PMCID: PMC8673364.
      Citations: 36     Fields:    
    500. McCullough PA, Whaley-Connell A, Brown WW, Collins AJ, Chen SC, Li S, Norris KC, Jurkovitz C, McFarlane S, Obialo C, Sowers J, Stevens L, Vassalotti JA, Bakris GL, Kidney Early Evaluation Program (KEEP) Investigators. Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Intern Med J. 2010 Dec; 40(12):833-41. PMID: 21199222.
      Citations: 3